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ABSTRACT 
 
Mucin 1 (MUC1) is a highly glycosylated membrane-bound protein normally expressed on the 
apical surface of ductal epithelial cells. During malignant transformation MUC1 acts as a Tumor-
Associated Antigen (TAA) by virtue of its overexpression, loss of polarity, and 
hypoglycosylation, allowing for T cell and antibody recognition of cryptic peptide epitopes 
derived from its extracellular domain. Almost all adenocarcinomas express abnormal MUC1 
making it an attractive target for cancer vaccines. However, vaccination of MUC1.Tg mice with 
a synthetic, unglycosylated MUC1 peptide (MUC1p) that mimics one tumor form of the 
molecule results in a weak anti-MUC1p immune response. WT mice receiving the same vaccine 
generate robust immunity to MUC1p, suggesting that it is viewed as a “self” antigen in 
MUC1.Tg mice, and apparently subject to peripheral tolerance. To globally query these distinct 
programs of immunity and tolerance induced by MUC1p in WT and MUC1.Tg mice 
respectively, we conducted whole transcriptome analysis of splenic RNA 24h and 72h after i.v. 
immunization of both mouse strains with MUC1p. We found that a new cohort of “pancreatic” 
enzymes (e.g. trypsin and CPB1) were expressed by splenic dendritic cells (DC) and regulated 
such that immunization with self-antigen suppressed their expression while foreign-antigens 
induced it within 24h post-vaccination. The relative expression of trypsin and CPB1 was highly 
correlated with the immunogenicity of the DC. Suppressed expression marked DC that were 
highly tolerized as demonstrated by low costimulatory molecule expression, limited motility, 
production of Aldh1/2, and preferential priming of naïve CD4+ T cells into Foxp3+ Treg versus 
IFNγ+ cells, while enhanced expression identified immunogenic DC. Deficient NFκβ pathway 
activation and enhanced STAT3 phosphorylation transcriptionally underlie tolerized DC along 
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with sustained expression of zDC. Trypsin was required for efficient degradation of the 
extracellular matrix, while CPB1 was required by DC to induce optimal, antigen-specific 
proliferation of CD4+ T cells. Importantly, these vaccine-induced changes in DC phenotype 
affected the entire splenic DC compartment, revealing an underappreciated role for endogenous 
DC in the transmission and amplification of vaccine-induced immunity or tolerance. These 
results underscore the importance of vaccine antigen choice and will contribute to rational 
vaccine design.  
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1.0  INTRODUCTION 
1.1 IMMUNE TOLERANCE TO SELF 
A major challenge for the developing immune system is to preclude the release of self-reactive 
lymphocytes into the periphery, thereby avoiding autoimmunity. Seminal work by Medawar and 
Burnet in the 1950’s proposed the clonal selection theory of tolerance to self-antigen (Ag) based, 
in part, on experiments demonstrating that immunization of fetal mice and chickens with cells 
derived from allogeneic animals conferred resistance against the rejection of grafts from the 
donor species later in life (1, 2). This hypothesis presumed that self-reactive lymphocytes were 
inactivated during embryonic development, resulting in an exclusively foreign antigen specific 
lymphocyte repertoire at the time of immunological maturity. The theory of central tolerance is 
now understood to ensure the development of T, B, NKT, and γδ T cells that recognize foreign 
peptides derived from pathogens and tumor cells rather than self-peptides. Central tolerance 
occurs in the thymus for developing T cells, and in the bone marrow for B cells. However, 
central tolerance is not completely efficient, and many potentially self-reactive lymphocytes 
escape to the periphery. Here, multiple checks and balances, referred to as peripheral tolerance, 
act to prevent an effector response against the host’s own antigens (3). Central and peripheral 
tolerance present challenges for the development of cancer vaccines, the goal of which is to 
induce immunity against tumor-associated antigens (TAA), many of which resemble the self-
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antigens against which mechanisms of central and peripheral tolerance act to preclude. We are 
interested in generating vaccine-induced immunity against the TAA Mucin 1 (MUC1). However, 
multiple layers of tolerance, including the presence of MUC1-specific regulatory T cells (Treg), 
and their preferential expansion after vaccination relative to that of MUC1-specific effector T 
cells (Teff) results suboptimal adaptive responses to MUC1 in both mice and humans (4-7).  
1.1.1 Central Tolerance 
After immature thymocytes leave the BM and traffic to the thymus they undergo two major 
rounds of selection: positive selection, and negative selection, or clonal deletion. After egress 
from the BM, CD4+CD8+ double positive thymocytes enter the thymic cortex where they rapidly 
scan cortical thymic epithelial cells (cTEC). Those that have moderate affinity for self-
peptide:MHC (pMHC) complexes receive a survival signal from the cTEC, while those with 
very low affinity for self-pMHC undergo so-called “death by neglect” (8, 9). The precise 
mechanisms by which cells are positively and negatively selected are incompletely understood, 
but may involve differences in both the conformational change and duration of signaling through 
the thymocyte TCR (9, 10). Cells with moderate affinity for self-pMHC upregulate expression of 
extracellular-signal-regulated kinase (ERK) and migrate to the thymic medulla in a CCR7-
dependent manner (9, 11). Because a subset of these positively selected cells are strongly 
autoreactive, medullary thymic epithelial cells (mTEC) and thymic DC (tDC) mediate negative 
selection via the presentation of diverse, self, peripheral tissue antigens (PTA). The presentation 
of extra-thymic antigens is mediated by the autoimmune regulator (AIRE), which allows mTEC 
to express a plethora of PTA through an imprecisely defined mechanism, but one that may 
involve the ability of Aire not to transactivate multiple PTA promoters, but to prevent stalling of 
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RNA Pol II on those promoters (12-14). Thymocytes with high affinity for self-antigen are 
deleted from the repertoire by apoptosis, initiated in part by decreases in mitochondrial anti-
apoptotic proteins (e.g.Bcl-2) and increases pro-apoptotic proteins (e.g. Bim) (15), while 
concurrently signaling through JUN-amino-terminal kinase (JNK) and p38 (16). While mTEC 
both express and present PTA on MHC I and MHC II, tDC are critical for cross-presentation of 
mTEC-derived PTA, and both populations require B7:CD28 interactions to mediate negative 
selection (17, 18). Underscoring the role of DC in mediating negative selection of self-reactive 
thymocytes, medullary tDC are capable of deleting autoreactive CD4+ T cells without 
contribution from mTEC or macrophages, and plasmacytoid DC (pDC) transport PTA to the 
thymus from the periphery and function as canonical mTEC (19, 20). Aire-mediated expression 
of PTA and ensuing tolerance is not limited to the thymus. Interestingly, lymph node stromal 
cells present PTA in the periphery and induce tolerance against gut-associated self-antigens 
independent of DC, demonstrating a functional overlap in maintaining self-tolerance between the 
thymus and the periphery (21). The efficiency of central tolerance in preventing the release of 
auto-reactive T cells is highlighted by experiments demonstrating that TCR.Tg CD8+ H-Y T cells 
recognizing the male antigen are detected in the periphery after transfer into female mice, but are 
deleted after transfer into males (22). Similarly, the importance of central tolerance is highlighted 
by the severe autoimmune syndrome polyendocrinopathy-candidiasis-ectodermal-dystophy 
(APCED) accompanying defects in Aire in humans (23).   
Natural, or thymic Treg (tTreg), defined as CD4+CD25hiFoxp3+ T cells assist in the 
contraction of an immune response after the elimination of a pathogen (24). However, they also 
preclude the development of spontaneous autoimmunity, as evidenced by the scurfy mouse that 
contains a mutation in the Foxp3 gene resulting in a non-functional Treg compartment (25). The 
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mechanisms by which Treg bearing high affinity TCR for self-antigen escape negative selection 
are imprecisely defined. Two recent studies demonstrate that CD70:CD27 interactions between 
tDC, mTEC, and thymocytes are required for the inhibition of apoptosis in Treg precursors, but 
not CD4+Foxp3- conventional T cells (26, 27). The mTEC in human MUC1.Tg mice (discussed 
in Section 1.5) express human MUC1, resulting in a higher frequency of MUC1-specific Treg 
compared to WT mice (6, 28). Therefore, MUC1 is a self-antigen and inducing immunity against 
it in MUC1.Tg animals must first overcome specific, Treg-mediated tolerance.  
1.1.2 Peripheral Tolerance: DC-Independent Mechanisms  
Thymic selection effectively deletes T cells with high-affinity to self-antigen, but both CD4+ and 
CD8+ T cells bearing TCR with low to moderate avidity for self peptides escape to the periphery 
where they can induce autoimmunity within a conducive inflammatory context (29, 30). 
Therefore, peripheral mechanisms exist to keep potentially auto-reactive T cells in check. The 
segregation of naïve T cells from most non-lymphoid tissues, referred to as immunologic 
ignorance, establishes a physical barrier precluding the interaction between an autoreactive TCR 
and the parenchyma that may express its cognate antigen. Naïve T cells traffic from the blood 
into secondary lymphoid organs through high endothelial venules (HEV). If they do not 
encounter a DC presenting cognate antigen, they drain into the efferent lymphatics, and are 
subsequently returned to the circulation via the thoracic duct, never having encountered antigens 
concentrated in non-lymphoid tissue (31).  
A second mechanism of peripheral tolerance, the efficient clearance of apoptotic cells, 
also involves compartmentalization or ignorance of self-antigens from potentially autoreactive T 
cells. Macrophages are chemoattracted to dying cells and phagocytose cellular corpses after 
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recognition of phosphatidyl serine on the dead cell’s membrane (32). Defects in multiple stages 
of this clearance process can lead to “leaky” apoptotic bodies, the proinflammatory release of 
DNA and self-proteins, and the pathogenesis of autoimmune disorders such as lupus and 
rheumatoid arthritis (33). In addition to shielding the immune system from intracellular contents, 
clearance of dying cells actively induces IL-10 and TGF-β production by macrophages, acting 
preemptively to counter the release of potentially immunogenic contents (34, 35).  
A third mechanism of peripheral tolerance is the induction of T cell anergy, or functional 
unresponsiveness to subsequent TCR ligation after the initial recognition of cognate pMHC 
occurs in a homeostatic or sub-immunogenic context. The priming of a naïve T cell into an 
effector cell requires the T cell to recognize its specific pMHC complex on an antigen-presenting 
cell (APC), referred to as Signal 1, followed by engagement of activating or inhibitory 
costimulatory molecules, referred to as Signal 2. (36). TCR engagement of pMHC in the absence 
of appropriate costimulation results in clonal anergy that prevents an autoreactive T cell from 
differentiating into an effector cell. The absence of costimulatory molecules on APC occurs in 
the steady state, or in a sub-inflammatory milieu. There are numerous costimulatory molecules 
that can inhibit both naïve and effector T cells at various points during, and after encounter with 
self-antigen. Naïve T cells constitutively express CD28, and the failure to receive signals from 
CD80 and CD86 (B7-1 and B7-2) on APC results in anergy (3, 37). Expression of CTLA-4, a 
higher affinity homolog of CD28 expressed by T cells after activation, acts to inhibit 
proliferation, IL-2 production, and induces anergy, preventing the prolongation of the effector 
response (38, 39). Finally, PD-1:PD-L1 interactions maintain anergy in previously activated 
autoreactive T cells after subsequent encounters with their self-antigens in parenchymal tissues 
(40). 
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Treg provide critical suppressive capacity when ignorance and anergy fail to prevent the 
induction of an autoimmune reaction. Originally identified as a CD4+CD25hi population with 
suppressive capacity (41), the importance of Treg in maintaining peripheral tolerance to self is 
illustrated by the extensive autoimmunity that develops in both mice and humans with a defect in 
Foxp3 (25, 42). Treg can develop in the thymus as discussed above, or can be primed from naïve 
CD4+ T cells in the periphery (iTreg) (43). While these two populations both express Foxp3 and 
possess a suppressive function, tTreg are mainly responsible for preventing T cell responses to 
self-antigens, while iTreg are generated de novo from naïve CD4+ T cells, and require IL-2 and 
TGF-β in conjunction with chronic, low-dose exposure to environmental antigens such as food-
derived antigens and the commensal microbiota (44-46). Knowledge of the precise mechanisms 
by which Treg mediate their suppressive effects is limited, however they appear to be diverse 
and involve both cell-contact as well as elaboration of suppressive cytokines. Constitutive 
expression of the high-affinity IL-2Rα (CD25) may function as a “sink”, depriving neighboring 
T cells of this crucial cytokine (47), while constitutive expression of CTLA-4 has been proposed 
to mediate trans-endocytosis of CD80 and CD86 on APC as well as preventing costimulation by 
those molecules via competitive occupancy (48). Treg express high levels of the adenosine 
ectonucleotidases CD39 and CD73 that decrease the availability of extracellular cyclic adenosine 
monophosphate available to effector cells (49). Treg-derived IL-10, TGF-β, and IL-35 all have 
suppressive functions in various mouse models of autoimmunity, mucosal tolerance, and 
lymphpoenic proliferation (43, 50). Interestingly, Treg also have direct, cytolytic activity both in 
vitro, and in vivo where they are required for the maintenance of skin allografts (51, 52).  
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1.2 DENDRITIC CELLS 
DC were identified in a series of seminal papers by Steinman and Cohn between 1973 and 1974 
(53-55). Steinman referred to them as “dendritic” because: “These novel cells can assume a 
variety of branching forms, and constantly extend and retract many fine cellular processes. The 
term ‘dendritic cell’ would thus be appropriate.” (53). While the precise mechanisms underlying 
DC function would not be elucidated for several years, based on their radiosensitivity, endocytic 
capacity, and lack of expansion following immunization with sheep red blood cells, Steinman 
postulated that, “These effects suggest a cooperative role for dendritic cells in the immune 
response” (54). Steinman was also the first to describe the ability of DC to induce T cell 
proliferation in vitro based on their stimulatory capacity in the mixed lymphocyte reaction 
(MLR) (56). However, it was not until Charles Janeway’s 1989 lecture at Cold Spring Harbor 
that the notion of co-stimulation, and its induction by microbial pattern recognition receptors 
(PRR) on APC attempted to unify the innate and adaptive mechanisms of host defense (57). 
Lanzavecchia and Mantovani categorized DC as innate based on their chemotaxis and calcium 
flux following exposure to complement and bacterial formyl peptides (58.) Following the 
discovery of TLR4 and its function as an endotoxin receptor, and its expression on DC, DC have 
been established as the most potent APC capable of bridging innate and adaptive immunity by 
sensing both microbial, and self-derived danger signals and priming the ensuing T cell response 
(59-61). 
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1.2.1 Induction of Immunity by DC 
Conventional DC (cDC) originate in the BM and can be subdivided into two major groups: 
migratory and lymphoid resident DC. Migratory DC undergo the canonical DC lifecycle, 
characterized by patrolling non-lymphoid tissue in an immature state, followed by maturation 
after detection of microbial and self-derived “danger” signals, and subsequent trafficking to 
draining lymph node (LN). During immaturity they are highly phagocytic, sampling their 
environments for pathogens and tumor cells. After detection of “danger” signals by PRR they 
begin to mature and process internalized proteins into MHC II and MHC I-restricted peptides 
(62). DC possess a plethora of PRR specialized for the detection of bacterial cell wall 
components and DNA, viral RNA, and fungal polysaccharides as well as molecules released 
from necrotic or physically damaged host cells. These receptors include the TLR, RLR, NLR, 
and CLR families amongst others (reviewed in (63)). Maturation is characterized by upregulation 
of a variety of costimulatory molecules including CD80, CD83, CD86 and CD40, as well as 
MHC II (61). These maturing DC upregulate expression of CCR7 and migrate through the 
lymphatics to the draining LN in response to gradients of CCL19 and CCL21 (64). After entering 
the LN through high endothelial venules, they present processed antigen to cognate CD4+ and 
CD8+ T cells in specialized T cell areas of secondary lymphoid tissues (65). Epidermal 
Langerhans cells, CD103- connective tissue DC and CD103+ DC of the dermis, lung, and gut are 
all prototypic migratory DC. In contrast, lymphoid tissue resident DC are not migratory and 
spend the entirety of their lifespan in LN, spleen, or thymus presenting both lymph-born self and 
foreign Ags, however they follow the same mechanisms of maturation and T cell priming as 
migratory DC. Tissue resident DC are less mature and more phagocytic compared to migratory 
DC (66). These lymphoid tissue resident DC can be phenotypically classified into three separate 
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populations, each with specific functionality. CD11c+CD4+CD8αα- DC, CD11c+CD4-CD8αα+ 
DC, and CD11c+CD4-CD8αα- DC (67). The CD11c+CD4-CD8αα +DC are a distinct lineage 
characterized by expression of the transcription factor Batf3, and are more efficient at cross-
presentation, the display of exogenously derived antigen on MHC I molecules to prime CD8+ T 
cells, while CD11c+CD4+CD8αα- DC are more efficient in presenting antigen to CD4+ T cells 
(68-70).  
 Following pMHC:TCR engagement with a cognate T cell (Signal 1), and ligation of 
costimulatory molecules (Signal 2), the DC is responsible for delivering all or part of Signal 3 
which comprises the cytokine signals required for T cell fate determination. DC are the earliest 
source of the T cell growth factor IL-2, and the absence of DC-derived IL-2 results in severely 
impaired T cell proliferation (71). DC provide IL-12 to skew naïve CD4+ T cells towards a Th1 
phenotype as well IL-6 and IL-23 to differentiate and stabilize cells towards the Th17 lineage 
(72, 73). DC also play an important role in the generation peripheral iTreg via the production of 
the suppressive cytokines IL-10, TGF-β, and  retinoic acid (RA) (74-76).  
 In addition to cDC, plasmacytoid DC (pDC) and monocyte-derived DC (moDC) 
comprise two additional populations. pDC are hematopoietically distinct from cDC and are a 
major sensor of viral infection and source of subsequent Type I IFN. pDC have recently also 
been described as important for the maintenance of self-tolerance, in part due to their low 
expression of MHC II and costimulatory molecules and inefficient phagocytosis (77, 78). 
Monocyte-derived DC are found in the circulation and are rapidly recruited to sites of infection 
and inflammation where they produce chemoattractants, inflammatory cytokines, and can 
participate in tissue repair, (reviewed in (79)). 
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1.2.1.1  Antigen Processing and Presentation 
 
Antigen processing and presentation are critical processes for DC function and are also important for  
tolerance or immunity to a given antigen. As discussed below, processing that results in MHC-restricted 
presentation of a peptide can induce immunity, while the complete degradation of an antigen during 
processing can result in a lack of thymic education and resultant autoimmunity. Similarly, the amount of 
peptide presented by a DC affects the type of T cell response that is primed (80).  
 MHC I processing of self-peptides occurrs in most somatic cells, and in DC via cross-presentation. 
Briefly, misfolded, viral, and tumor-associated proteins are ubiquitylated and degraded by the cytosolic 
proteasome. Proteasomal catalytic subunits, 1, 2, and 5 hydrolyze peptides after acidic, basic, and 
hydrophobic residues respecitvely (81). IFN induces assembly of the immunoproteasome (expressed 
constituitively by APC) via expression of the i subunits LMP2/7/10 that produce peptides tailored for 
priming a CD8+ response (82) Further N-terminal trimming can occur via cytosolic peptidases such as 
tripeptidyl peptidase II (TPPII), before transporter associated with antigen processsing (TAP) mediated 
translocation into the ER. Additional N-terminal processing by the endoplasmic reticulum-associated 
amino peptidase (ERAAP) precedes chaperone-mediated (tapasin/Erp57/calnexin) loading of peptides 
onto MHC I molecules for transport to the cell surface (83) (84) (85) (Fig. 1). The diversity of proteases 
responsible for generating MHC I peptides is beginning to be further elucidated as evidenced by the 
identification of insulin-degrading enzyme (IDE), a cytosolic metallopeptidase, being involved in 
generating TAA MAGE-A3-derived epitopes in a proteasome-independent fashion (86). MHC II 
processing is conducted predominantely by professional APC (DC/macrophages/B cells), and results in 
presentation of exogenously or endogenously derived Class II restricted antigen via classical or 
autophagic pathways respectively. In the classical pathway, antigen moves from phagocytic 
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compartments through a series of progressively more acidic endosomal vesicles that process the protein 
and facilitate its loading onto MHC II. Briefly, internalized antigen is transported to the late 
endosomal/lysosomal-like MHC II compartment (MIIC), where the MHC II chaperone invariant chain 
(Ii, CD74) is cleaved by cathepsin S (CatS) (87) to the shorter, class II associated invariant chain peptide 
(CLIP). After proteolytic cleavage by a multitude of proteases including serine proteases Cat A/G, 
aspartyl proteases Cat D/E, cysteine proteases Cat B/S/L and asparaginyl endopeptidase (AEP), the 
chaperone HLA-DM mediates exchange of CLIP for antigenic peptides (88) (89) (90) with subsequent 
targeting of peptide-MHC II complexes to the cell membrane via endolysosomal tubules (Fig.1). There 
is both redundancy and specificity in cathepsin-mediated antigen processing. CatB or CatD deficiency 
does not impair presentation of the model antigens OVA or HEL to Class II restricted hybridomas (91). 
However, AEP is required for B cell processing and immunity against tetanus toxin (92), while the 
absence of CatD in vitro improves IL-2 production by myoglobin-specific CD4+ cells (93). Cat activitiy 
in vivo also appears to posess specificity as AEP can destroy myelin basic protein (MBP) in mTEC and 
thymic DC, precluding negative selection against MBP-reactive T cell clones leading to autoimmunity. 
(94). This accounts for data suggesting that control of vesicular acidification, and therefore lysosomal 
enzymatic activity, are important in preventing destruction of immunogenic epitopes (95). Manipulation 
of antigen processing enzymes for therapeutic benefit has been used with sucess in mouse models of 
experimental autoimmune encephalomyelitis (EAE) (96) and Sjögren syndrome (97) with inhibitors of 
CatS. Conversely, induction of the processing/presentation machinery in tumors by IFN increases the 
efficacy of immunotherapy in both mice and humans, illustrating the potential of manipulation of this 
pathway for clinical benefit (98, 99).  
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Figure 1 MHC I and MHC II antigen processing and presentation pathways. 
(Left Panel) Endogenously or exogenously (through cross-presentation)-derived proteins 
destined for presentation on MHC I are processed predominantly by the cytosolic proteasome 
complex before chaperone-mediated translocation and loading in the ER. (Right Panel) Peptides 
to be presented on MHC II molecules originate extracellularly and are processed and loaded via 
the endosomal pathway.  Reprinted with permission from: Jensen, P.E. Nature Reviews 
Immunology. 2007. 
1.2.2 Peripheral Tolerance: DC-Dependent Mechanisms 
As discussed above, DC play important roles in central tolerance to self. In the periphery, DC are 
indispensible for precluding autoimmunity, in large part by inducing anergy or deletion of T 
cells, promoting the differentiation of iTreg, and producing suppressive factors (100). The 
importance of the DC contribution to the maintenance of homeostatic tolerance is highlighted by 
the autoimmunity, mediated by CD4+ T cells, that occurs after their ablation (101), although this 
role is still somewhat contentious (102). Immature DC (iDC) promote tolerance in the steady 
state via their low expression of the costimulatory molecules CD80, CD86 and CD40, as well as 
MHC II (103, 104). T cells that recognize pMHC complexes on iDC in the absence of sufficient 
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costimulation are rendered anergic or are deleted. Similarly, the amount of antigen presented by 
a DC can determine the direction of the ensuing T cell response, independent of maturational 
state, with low doses of antigen favoring Treg differentiation and high doses favoring effector 
cells (105). 
 In addition to iDC, several DC subsets have been described as being tolerogenic in the 
absence of inflammation or infection. In mice, CCR9+ pDC express low levels of MHC II and 
costimulatory molecules and mediate tolerance to allografts and oral antigen by priming Treg 
(106, 107). Splenic CD11c+CD11b-CD205+CD8αα+ DC are specialized to induce tolerance 
against self-antigens, in part through their enhanced production of TGF-β, and in vivo targeting 
of antigen to this population using peptide conjugated to anti-CD205 antibodies induces antigen-
specific Treg and tolerized CD8+ T cells (75, 104, 108, 109). The DC associated with mucosal 
barrier sites such as the gut must maintain tolerance to commensal and food-derived antigens in 
the context of chronic exposure to these beneficial, yet foreign molecules. As a result, the 
CD11c+CD103+ DC in the intestinal lamina propria are specialized to induce Treg via a TGF-β 
and retinoic acid (RA)-dependent mechanism (76). Finally, human CD123+ DC and mouse 
CD19+ DC expressing indoleamine 2,3-dioxygenase (IDO), an enzyme responsible for 
tryptophan catabolism, can inhibit T cell proliferation in vitro have been detected in vivo as well 
where they may provide important suppressive functions (110, 111). Therefore, during 
homeostasis, the primary role of iDC is to prevent the priming of autoimmune responses, and 
these non-inflammatory cells are assisted by additional, specialized tolerogenic DC populations. 
It is important to note that iDC, pDC, CD11c+CD11b-CD205+CD8αα+ DC, and CD103+DC all 
have the potential to induce potent, Th1, Th17, or Type I IFN responses during inflammatory 
insult or infection, yet in the steady state are uniquely equipped to preclude those responses that 
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would like be directed against the host. For example, CD103+DC from colitic mice induce IFNγ 
production rather than Foxp3+ Treg when transferred into naïve animals, highlighting the 
importance of the microenvironmental milieu (resulting from infection or vaccination) in 
conferring DC with tolerogenic versus immunogenic properties (112). 
DC express a wide variety of innate immune receptors that generally induce maturation 
and immunogenicity upon recognition of microbial or host-derived danger signals. However, 
signaling through some of these receptors maintains a quiescent state, or actively induces DC 
tolerance. Signaling through TLR2 by yeast zymosan and phosphatidylserine from Schistosoma 
sp. induce Treg differentiation, while ligation of the TAM receptor tyrosine kinase Mer by 
ligands on the surface of apoptotic cells actively inhibits DC maturation (Fig. 2) (100, 113). 
After a DC is rendered tolerogenic, inherently by virtue of immaturity, after ligation of 
tolerizing receptors, or by belonging to a CD11c+ compartment specialized to maintain tolerance 
as discussed above, the DC can effect that tolerance through the production of 
immunosuppressive cytokines, or by the lack of production of immunogenic cytokines. The 
pulmonary DC of mice exposed to airway allergens produce suppressive IL-10 versus Th1-
skewing IL-12p70, as do DC isolated from the peyers patches in the gut to prevent the 
development of airway hypersensitivity and contribute to oral tolerance respectively (74, 114). 
Similarly, the suppressive cytokine TGF-β produced by DC is required for control of 
experimental autoimmune encephalitis in mice (115) while DC-derived retinoic acid (RA) is a 
key driver of Treg development in the gut and has broad immunosuppressive effects on diverse 
cell types (Fig. 2) (116). Arginase, an enzyme that metabolizes L-arginine to L-ornithine and 
urea, has immunosuppressive effects on T cells and is produced by DC. Specifically, DC 
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production of arginase has been shown to be directly induced by RA, suggesting a feed-forward 
mechanism exploited by the suppressive, CD103+ DC in the gut (117).  
The transcriptional programs that underlie DC tolerance and immunity are not completely 
characterized, though some important players have emerged. In common with many cells, 
activation of the NFκβ pathway, specifically translocation of phospho-p65 into the nucleus, is 
essential for the upregulation of costimulatory molecules and MHC II in DC (118) Recently, the 
transcription factor Zbtb46 (zDC) has been shown to be constitutively expressed by iDC in the 
steady state and rapidly downregulated after TLR-induced maturation, however the promoters it 
occupies are currently unknown (119, 120). The highly tolerogenic DC (and macrophages) found 
in the lamina propria of the intestine require the constitutive activity of β-catenin to produce RA 
and IL-10, as well as for maintenance of Foxp3+ Treg from naïve CD4+ T cells (121). Similarly, 
a novel role for histone deacetylase 11 (HDAC11) had been described in negatively regulating 
transcription of IL-10 in human DC and murine macrophages (122). The signal transducer and 
activator of transcription (STAT) proteins signal downstream of multiple cytokine receptors. 
STAT3 is phosphorylated in response to IL-10 signaling, amongst other cytokines, and its 
deletion in DC confers a mild autoimmune phenotype in mice demonstrating its role as a 
negative regulator of DC immunogenicity (123). Important negative regulators of cytokine 
signaling in DC and other hematopoietic cells are the suppressor of cytokine signaling proteins 
(SOCS) that bind to janus tyrosine kinases (JAK) inhibiting signaling after a cytokine binds to its 
receptor (124). Accordingly, tolerized DC upregulate expression of SOCS1 resulting in 
decreased production of the proinflammatory cytokines TNF-α, IFNγ, and IL-12 (125).  
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Figure 2 Mechanisms of DC tolerization and tolerogenicity 
Recognition by DC of microbial and self-derived molecules can induce tolerance depending on 
the inflammatory milieu in which it occurs, while some tolerance (e.g. the clearance of apoptotic 
bodies and tolerance to oral antigen) occurs independently of inflammation. Reprinted with 
permission from Manicassamy, S. Immunological Reviews. 2011. 
1.2.3 DC Vaccines 
Given their central role in priming antigen-specific T cell responses, DC are uniquely suited to 
be used as both prophylactic and therapeutic vaccines for cancer, pathogens, autoimmunity, and 
transplantation. Recently, the first DC vaccine for clinical use was approved by the FDA for the 
treatment of metastatic prostate cancer (126). The vaccine, Sipuleucel-T, consists of the patient’s 
autologous PBMC cultured for three days with a prostatic acid phosphatase-GM-CSF fusion 
protein, and is administered bimonthly for six weeks. Sipuleucel-T increased the median survival 
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time of patients by 4.1 months, a notable result given the relative immunogenicity of many 
prostate tumors compared with other malignancies. There are 3 general approaches to DC 
vaccination that are currently in use: the use of autologous (clinical) or syngeneic (preclinical) 
DC that are loaded with the antigen(s) against which the ensuing T cell response is to be 
directed, and then matured, and reinfused into the patient/animal, the targeting of antigen to 
specific DC populations in vivo using chimeric antigen-antibody complexes, and the 
manipulation of DC function by antibody/ligand-mediated engagement of DC 
stimulatory/inhibitory molecules (127). Autologous, peptide-pulsed DC vaccines for cancer, 
HIV, and hepatitis C have been demonstrated to be safe, effective at inducing antigen-specific 
CD4+ and CD8+ T cells, and in some cases, eliciting objective clinical responses (128-131). 
“Negative vaccination”, or the use of autologous, tolerized/tolerizing DC to prevent autoimmune 
pathologies such as rheumatoid arthritis and type 1 diabetes, as well as to prevent transplant 
rejection have also been shown to be safe, but with varying degrees of efficacy (132-134). Some 
tolerance-inducing vaccines rely on the ability of iDC, either peptide loaded or unloaded, to 
prime Treg rather than effector T cells. Others rely on pharmacologically manipulated DC (e.g. 
using rapamycin, dihydroxyvitamin D3, or prostaglandin E2) to induce tolerogenic DC by 
preventing maturation and/or IL-12p70 production (135).  
Targeting antigen to DC in vivo is an attractive strategy by which to take advantage of 
different DC subsets and their specialized functions. For example, CD8α+DEC-205+ DC are 
specialized to cross-present antigen to CD8+ T cells (68, 109), while CD8α-DEC-205-DCIR2+ 
DC preferentially present antigen to CD4+ T cells (69). Targeting ovalbumin specifically to 
DEC-205+ DC using an antigen-conjugated antibody in vivo leads to improved rejection of 
OVA+ tumors as well as viral clearance (136). Similarly, targeting the TAA Her-2/neu to 
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CD11c+ DC in vivo resulted in both protection against subsequent challenge with a Her-2/neu+ 
transplantable tumor, as well as a delay in the growth of spontaneous tumors in Balc-neuT mice 
(137). The ability to inhibit tumor growth by targeting antigen to DC, in the context of tolerance 
to transgenically expressed Her-2/neu, suggests that vaccines that target DC in vivo v can break 
self-tolerance.  
The plethora of PRR expressed by DC to detect molecules derived from microbes and 
damaged host cells can also be exploited to induce DC maturation, and thus enhance their 
immunogenicity. These include synthetic TLR ligands such as Poly:ICLC (TLR 3), Imiquimod 
(TLR 7/8), and CpG dsDNA (TLR 9) (138). Many of these adjuvants used to mature vaccine DC 
ex vivo can also be administered systemically to mediate global DC maturation. Similarly, 
agonistic antibodies directed against activating costimulatory molecules such as CD40, or 
inhibitory molecules such as ASGPR1 can be administered to the host before or after infusion of 
matured DC (139, 140).  
1.3 IMMUNOSUPPRESSION AND CANCER 
1.3.1 Tumor-Mediated Immune Suppression  
Portions of Sections 1.3.1 and 1.4.2 have been adapted from “Vaccines based on abnormal self-
antigens as tumor antigens: Immune regulation”. Farkas, AM and Finn OJ.  Seminars in 
Immunology. 22:125-131. 2010. Reprinted with permission from Elsevier, Amsterdam. 
Copyright permission is kept on file with Adam M. Farkas. 
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Cancer vaccines must overcome the strongly immunosuppressive milieu created by the tumor 
itself. Tumor cells can prevent an effective immune response through a multitude of mechanisms 
(141). Firstly, transformed cells can produce soluble immunosuppressive factors such as IL-10, 
Transforming Growth Factor  (TGF-), gangliosides and Prostaglandin E2 (PGE2) that all 
diminish the potency of effector cells. Tumor cells can also directly mediate the killing of T cells 
through expression of Fas-L, Tumor Necrosis Factor Apoptosis-Inducing Ligand (TRAIL), and 
Indolamine 2 3-Dioxygenase (IDO) production, as well as provide negative co-stimulation to 
tumor-specific T cells through B7-CTLA-4 and Programmed Death Ligand (PD-L1) receptor 
(PD-1) interactions. These interactions recruit SHP family members to de-phosphorylate the 
Immunoreceptor Tyrosine-Based Activation Motif (ITAM) responsible for signal transduction 
through the TCR (142). Tumor cells are also able to downregulate MHC I expression, leading to 
their sub-optimal recognition by effector cells through the loss of TCR-MHC avidity and 
impaired tumor antigen processing and presentation (143).  
Expansion of Myeloid-derived suppressor cells (MDSC) is another mechanism by which 
tumor-specific effector T cell immunity is dampened. MDSC, characterized as a heterogeneous 
population of Gr-1+CD11b+ cells in mice (144) and CD11b+CD33-/loHLA-DR-/lo cells in humans 
(145) are present at higher frequencies in the blood of tumor-bearing mice and humans (146). 
MDSC arise from common myeloid progenitors in the bone marrow (BM) that in healthy 
animals differentiate into macrophages, dendritic cells and granulocytes under the influence of 
GM-CSF, FMS-related tyrosine kinase 3 (FLT3) and IL-3 (147). However, the cytokine and 
growth factor milieu produced by tumors, including VEGF, TGF, IL-10 and COX-2, supports 
the maintenance of an immature phenotype and antigen-specific suppressor function. MDSC 
express MHC I but little MHC II or co-stimulatory molecules, such that presentation of Class I 
 20 
restricted, tumor-derived peptides to CD8+ cells results in inhibition of IFN production and lack 
of CTL activity (148).  MDSCs mediate their suppressive effect through additional mechanisms 
including high level arginase expression (thus depleting the pool of L-arginine requisite for 
effector cell proliferation), iNOS (increasing T cell apoptosis via nitric oxide), peroxynitrite, and 
reactive oxygen species (ROS) (149) (147). MDSC have also been demonstrated to elicit 
peripheral Treg (150).  
1.3.2 Tumor-Mediated Immune Suppression and DC 
Many of the tumor-derived mechanisms of immunosuppression that affect tumor recognition and 
T cell effector function also inhibit the immunogenicity of DC, and thus preclude the priming of 
robust anti-tumor immunity (146, 151). Tumor-derived IL-10, TGF-β, and PGE2 can all render 
DC refractory to maturation by the danger signals released from dying tumor cells as well as 
vaccination, leading to low expression of CD80, CD86 and MHC II (152) and reviewed in (141). 
As discussed above, this immature DC phenotype results in the priming of Treg rather than 
IFNγ+ anti-tumor CD4+ and CD8+ T cells (153) and often mechanistically involves the induced 
expression of TGF-β by DC (154). IL-10 produced by the tumor as well as DC appears to play a 
critical role in the ability of DC to prime cytotoxic lymphocytes (CTL) as IL-10-/- mice are 
resistant to UV-induced melanoma, and vaccination of mice using BMDC derived from IL-10-/- 
mice induces tumor rejection and specific memory (155, 156). Additionally, the tumor 
microenvironment is generally hypoxic, acidic, and contains byproducts of anaerobic metabolism 
such as lactate. This milieu affects the ability of DC to infiltrate solid tumors, thereby reducing 
the antigen presentation capacity within the tumor, and also predisposing the priming of a Th2-
biased T cell response that has little anti-tumor effect (157, 158). A final, major contributor to 
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DC immunosuppression induced by tumors is altered myelopoeisis resulting in inefficient 
production of mature DC in the BM in favor of immature DC precursors, and a corresponding 
defect in the number of tumor-infiltrating DC (146). The reduction in DC number and tumor 
localization, combined with the inability to functionally mature and prime T cells results in a 
highly immunosuppressive milieu for therapeutic cancer vaccines to overcome.  
1.4 MUC1 AS A TUMOR-ASSOCIATED ANTIGEN (TAA) 
1.4.1 MUC1 Background  
MUC1 is a highly O-glycosylated, trans-membrane protein expressed on the apical surface of 
ductal epithelial cells (Fig. 3). It is a constituent of the mucous layer in the gut and respiratory 
tracts along with the secreted mucins, thus protecting epithelial cells from pathogens, ROS, and 
toxins (159, 160). It is comprised of an extracellular domain consisting of 20-120 repeats of a 
conserved 20mer sequence (PDTRPAPGSTAPPAHGVTSA) called the variable number of 
tandem repeats (VNTR) region, that remains silent to the immune system during homeostasis, 
due to inaccessibility to APC, lack of efficient processing by DC (161), and the masking of 
peptide epitopes by the long, branched sugars attached at Ser and Thr residues within the VNTR. 
During malignant transformation and chronic inflammatory disorders, MUC1 loses the polarity 
of its expression, becomes overexpressed, and is extensively hypoglycosylated. These shorter, O-
linked glycans represent conserved, neo-antigens such as the Tn antigen (GalNAcα-O-S/T) and 
the Tf antigen (Galβ1-3GalNAc-O-S/T) (162). Hypoglycosylation reveals previously masked 
peptide epitopes that potentially represent “foreign” or “abnormal self” antigens on MUC1. 
 22 
Because these cryptic peptide epitopes are selectively expressed on transformed epithelial cells, 
they represent an attractive target antigen for cancer vaccines (162-164).  In addition to its role as 
a TAA, MUC1 also functions as an oncoprotein via its cytoplasmic tail. The inducible expression 
of MUC1 by proinflammatory cytokines such as IFNγ, TNF-α and IL-6 results in direct 
activation, by the cytosolic tail of MUC1, of p65, p53 and β-catenin (165-167). More recently it 
has been demonstrated that the extracellular domain of MUC1 can induce transcription of IL-6 
and TFN-α by associating with NFκβ (168). Through these interactions, MUC1 can enhance 
tumor progression in a feed-forward loop driven by its overexpression on transformed cells. 
 
 
 
Figure 3 Biochemical structure of MUC1. 
The extracellular VNTR region of MUC1, as well as detail of the membrane-proximal domain, 
transmembrane domain, and cytoplasmic tail are depicted. The 20 circles represent 1 repeat of 
the repetitive 20mer with open circles depicting Ser and Thr residues that can be glycosylated 
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with O-linked sugar moieties. Filled circles in the cytoplasmic tail represent Tyr residues with 
the adaptor/signaling molecules shown to interact with each Tyr depicted below. Figure reprinted 
with permission from: Kimura, T. and Finn, OJ. Expert Opinion on Biological Therapy. 2013.  
 
1.4.2 MUC1 Vaccines in Clinical Trials 
The first clinical trial (Phase I) using a MUC1 based vaccine enrolled 22 patients with advanced 
adenomas of the breast, pancreas, and colon (169). The vaccine was composed of a 105 amino 
acid synthetic MUC1 peptide admixed with BCG adjuvant and administered subcutaneously. 
While there was no survival benefit, the vaccine was safe and there was a 2-4 fold increase in 
MUC1-specific CTL’s in 7 patients as well as an increase in anti-MUC1 IgM in a fraction of 
patients. The inability of this vaccine to induce effective anti-tumor immunity likely involved 
multiple immune system intrinsic and tumor intrinsic suppressive mechanisms given the 
advanced stage of disease in all patients. Low levels of MUC1-specific IgM illustrate a failure to 
activate CD4+ T cells required for isotype class switching and the IFN production requisite for 
efficient CTL expansion.  
Another trial (Phase I/II) used a MUC1 peptide 100mer in combination with the SB-AS2 
adjuvant (monophosphoryl lipid A in alum and water) in patients with locally advanced or 
surgically resected pancreatic cancer with no prior chemotherapy (7). The vaccine was 
administered i.m. at 3 week intervals, and was again well tolerated. Two of 16 patients were 
disease free at 32 and 61 month follow-ups. Notably, there was a significant increase in the 
number of CD8+ T cells in the peripheral blood of the vaccine group able to make IFN in 
response to polyclonal activation, perhaps representing a vaccine-mediated effect on reducing 
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systemic immunosuppression. Importantly, these patients initially had less advanced disease 
compared with the trial discussed above, and the induced immunity was likely not subject to the 
same suppressive mechanisms as are present in more advanced cancers. There was also an 
increase in T cell infiltrate post-vaccination in skin biopsies, and the first observed induction of 
MUC1-specific IgG in 5 patients. The improved response as far as clinical outcome and specific 
IgG might represent the enhanced efficacy of vaccination in earlier stage disease before tumor-
intrinsic mechanisms of immune regulation become more entrenched.  
A more recent MUC1 vaccine (PhaseI/II) was tested in patients with surgically resected 
pancreatic or biliary cancers (129). The vaccine consisted of MUC1 peptide-pulsed autologous 
DC’s administered intradermally or subcutaneously. Four of 12 vaccine recipients remained alive 
and disease free 4 years post-completion of the study, representing significantly improved 
survival compared to conventional treatments. Immunologically, there was an increased 
frequency of Treg in patients receiving the vaccine compared with healthy, age-matched controls 
that was transiently increased following each vaccination as previously observed in mice (4). 
However, the vaccine did not reduce Treg, and the ability to examine MUC1-specific IFN 
production from CD4 and CD8 cells in the peripheral blood was difficult to assess against a high 
basal level of T cell activation. This may illustrate the vaccine’s ability to non-specifically 
reduce suppression in these patients, which translated into the positive clinical outcomes that 
were observed. No increase in MUC1 specific IgG or IgM was observed, though as a cellular 
vaccine this was not its primary goal (i.e. soluble antigen was not delivered). The lack of 
detectable change in conventional correlates of protection, combined with favorable outcome 
leads to the question of how best to monitor the induction of immunity. One hypothesis is that 
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cells of the peripheral blood may not be representative of the induction of effective immunity 
due to the presence of micro-metastases that imprint a suppressive phenotype on these cells.  
A Phase II trial involving a vaccine against MUC1 in prostate cancer made use of a 
modified vaccinia virus vector (rMVA) encoding MUC1p and IL-2 (170). The primary endpoint 
was a 50% increase in PSA doubling times and was not achieved, however 13 of 40 patients had 
a 2+ fold increase in PSA doubling time and 10 maintained stable PSA levels for 8 months with 
a median improvement of 1.6 moths. Interestingly, while 7 individuals developed MUC1-
speicific CD8+ T cells post-vaccination, over half of the patients had MUC1-specific CD8+’s pre-
vaccination. This observation likely reflects the immunoregulatory cancer microenvironment that 
prevents endogenous TAA-specific T cells from mediating effective immunity. Indeed, the 
positive results in this trial may have resulted not from the successful priming of new TAA-
specific T cells but rather the elicitation of additional IL-2. 
MUC1 is also aberrantly expressed in Non-Small-Cell Lung Cancer (NSCLC) and a 
Phase IIB trial was conducted in individuals with advanced (Stages IIIB and IV) disease 
following first-line chemotherapy (171). The vaccine used a liposomal vector (BLP25) to deliver 
MUC1 in conjunction with a monophosphoryl lipid A adjuvant via subcutaneous injection. 
Vaccine was administered weekly to four anatomic sites to increase the amount of MUC1 
present in relevant draining lymph nodes. Although 98.9% of patients receiving the vaccine 
reported adverse effects (AE), 95.2% of the control subjects did also suggesting that the majority 
of AE are NSCLC related and not due to vaccination. Once again, no symptoms of autoimmunity 
were observed. While this trial did not reach statistical significance, individuals who received the 
vaccine showed a median improvement in survival time of 4.4 months. Interestingly, vaccinated 
patients with stage IIIB disease had a 2-year survival rate of 60% compared to 36.7% for the 
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control group. The vaccine induced MUC1-specific T cell proliferation in only 16 of 78 
individuals (20.5%). Only 2 of these 16 patients had stage IIIB disease, suggesting that a specific 
proliferative response is not predictive or mechanistically correlated with the stage-specific 
survival benefit observed. This highlights the difficulty of identifying immunologic parameters 
that can be used as hallmarks of vaccine efficacy, however the results of this trial are promising 
for the use of TAA vaccination for therapy of solid tumors.  
Because the immunosuppression present in patients with pre-existing tumors decreases 
the immunogenicity of targeted, therapeutic vaccination, a recent study used prophylactic 
vaccination against MUC1 as a new strategy. Thirty-nine patients with a history of pre-malignant 
colonic adenomas were immunized with MUC1p and Poly:ICLC, a TLR3 agonist. 17/39 
developed MUC1-specific IgG while the 22/39 who did not had concurrently high circulating 
levels of myeloid-derived suppressor cells (MDSC) (172). This study demonstrated both the 
immunogenicity of MUC1p as an antigen as well as an early immunosuppressive state associated 
with pre-malignant lesions that affects vaccine efficacy in a manner similar to frank cancer.  
1.5 MUC1.TG, VFT, AND RFT MICE 
Human and murine MUC1 share just 34% amino acid homology in the VNTR region (160). 
Therefore, to examine the efficacy of various MUC1-based vaccines, the human MUC1.Tg 
mouse was created. MUC1.Tg mice express human MUC1 under transcriptional control of its 
endogenous promoter, with the cellular distribution and transformation-induced 
hypoglycosylation recapitulating that observed in humans (173, 174). mTEC in MUC1.Tg mice 
present a variety of MUC1 peptides to developing thymocytes, including peptides recognized by 
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antibodies specific for unglycosylated and hypoglycosylated MUC1 (28). As a result, MUC1 is a 
self-antigen in MUC1.Tg mice, and this is reflected in the hyporesponsiveness to vaccination 
with a synthetic, naked peptide derived from the VNTR region of human MUC1 (MUC1p) in 
these animals (4, 5, 173, 175). However, tumor-associated, hypoglycosylated MUC1 (TnMUC1) 
behaves as a foreign, or abnormal-self antigen, and immunization of both WT and MUC1.Tg 
mice with DC loaded with TnMUC1 elicit comparable immunity (5, 176).  
  To examine MUC1-specific T cell responses to vaccination with MUC1p and TnMUC1, 
two CD4+ TCR.Tg mice were generated. VFT mice have an MHC II-restricted TCR that 
recognizes an epitope derived from the extracellular tandem repeat region of human MUC1 
(MUC1p). RFT mice have an MHC II-restricted TCR that recognizes an epitope derived from 
the extracellular region of human MUC1 decorated with O-linked GalNac residues (TnMUC1) 
(5, 176).  
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1.6 INTRODUCTION TO THE PROJECT 
Background: The ability to induce immunity against the tumor-associated antigen MUC1 has 
broad implications for cancer vaccines, both therapeutic and prophylactic. However, previous 
work has identified deficient proliferation of MUC1 peptide-specific CD4+ T cells after 
immunization of MUC1.Tg mice with MUC1p. This defect is not observed in immunized WT 
mice suggesting that MUC1p is viewed as “self” in the MUC1.Tg system while being “foreign” 
in WT (5). Central tolerance was ruled out by previous work in the lab and several mechanisms 
of peripheral tolerance were suggested. One mechanism was a higher Treg:Teff ratio in 
immunized MUC1.Tg mice, and could be corrected by transferring Treg-depleted CD4+ T cells 
into MUC1.Tg mice pre-immunization (4). Similarly, concurrent activation of CD4+ T cells 
specific for “foreign” peptide antigen (i.e., OT-II) could rescue the proliferation of MUC1p-
specific CD4 T cells (5, 176). To globally query early, additional mechanisms of peripheral 
tolerance to MUC1p we vaccinated WT and MUC1.Tg mice with DC loaded with MUC1p and 
conducted total gene expression analysis of the spleen at 24 and 72h post-immunization. We 
found that expression of a number of “pancreatic” enzymes was suppressed in splenic DC from 
MUC1.Tg mice immunized with MUC1p, while their expression in splenic DC from immunized 
WT mice was dramatically increased. Based on this data we hypothesize that: Vaccine-induced 
upregulation in splenic DC, of a cohort of catabolic enzymes previously characterized as being 
pancreas-restricted in expression, is an early biomarker of DC that will prime strong immunity 
(i.e., in response to a foreign antigen), and is highly correlated with an immunogenic DC 
phenotype and function. Conversely, vaccine-induced suppression of these enzymes is an early 
biomarker of DC that will promote tolerance (i.e., in response to a self-antigen), and is highly 
correlated with DC that acquire a tolerogenic phenotype and function. 
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Specific Aims  
 
Specific Aim 1:  Analyze expression of “pancreatic” enzymes in DC post-vaccination with self 
versus foreign antigen in two mouse models: MUC1.Tg mice that are hyporesponsive to 
immunization with MUC1p, and RIP.OVA mice that are hyporesponsive to immunization with 
ovalbumin. Correlate the pattern of protease expression with the phenotype and function of 
splenic DC post-immunization with MUC1p or OVA respectively (i.e., cytokine production, co-
stimulatory molecule expression, interaction with other cellular compartments, motility, and 
ability to prime naïve CD4+ T cells into distinct lineages).  
 
Specific Aim 2: Define the intracellular signaling pathways in DC that determine their 
immunogenic versus tolerogenic phenotype and function in response to immunization of 
MUC1.Tg mice with MUC1p and ovalbumin as representative self or foreign antigens. 
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2.0  ANTIGEN CHOICE DETERMINES VACCINE-INDUCED GENERATION OF 
IMMUNOGENIC VERSUS TOLEROGENIC DC THAT ARE MARKED BY 
DIFFERENTIAL EXPRESSION OF PANCREATIC ENZYMES 
Portions of Chapter 2 are adapted from “Antigen choice determines vaccine-induced generation 
of immunogenic versus tolerogenic dendritic cells that are marked by differential expression of 
pancreatic enzymes”. Farkas, AM, Marvel DM, and Finn, OJ. 190: 3319-3327. 2013. Copyright 
2013. The American Association of Immunologists, Inc. Copyright permission is kept on file 
with Adam M. Farkas. 
2.1 ABSTRACT 
Dendritic cells (DC) elicit immunity to pathogens and tumors while simultaneously preserving 
tolerance to self. Efficacious cancer vaccines have been a challenge because they are based on 
tumor antigens, some of which are self-antigens and thus subject to self-tolerance. One such 
antigen is the tumor-associated mucin MUC1.  Preclinical testing of MUC1 vaccines revealed 
existence of peripheral tolerance to MUC1 that compromises their efficacy.  To identify 
mechanisms that act early post-vaccination and might predict vaccine outcome, we immunized 
human MUC1 transgenic mice (MUC1.Tg) i.v. with a MUC1 peptide vaccine against which they 
generate weak immunity, and WT mice that respond strongly to the same peptide. We analyzed 
differences in splenic DC phenotype and function between the two mouse strains at 24 and 72 
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hours post-vaccination, and also performed unbiased total gene expression analysis of the spleen. 
Compared to WT, MUC1.Tg spleens had significantly fewer DC and they exhibited significantly 
lower expression of co-stimulatory molecules, decreased motility and preferential priming of 
antigen-specific Foxp3+ regulatory T cells (Treg).  This tolerogenic DC phenotype and function 
was marked by a new putative biomarker revealed by the microarray: a cohort of pancreatic 
enzymes (trypsin, carboxypeptidase, elastase and others) not previously reported in DC.  These 
enzymes were strongly upregulated in the splenic DC from vaccinated WT mice and suppressed 
in the splenic DC of vaccinated MUC1.Tg mice.  Suppression of the enzymes was dependent on 
Treg and on signaling through the IL-10 receptor and correlated with global down-regulation of 
DC immunostimulatory phenotype and function. 
2.2 INTRODUCTION 
Dendritic cells (DC) are potent inducers of antigen-specific T cell responses and are the major 
cell type responsible for priming naïve T cells (61, 177). As such, they have been central to 
vaccination strategies aimed at inducing immunity to both pathogens and tumors (127, 178). 
However, DC are also important in the maintenance of homeostatic tolerance to self-antigens 
(Ag) (179). A large body of literature has established the ability of DC to actively induce 
immunological tolerance against self-Ag, and those closely related to self, thus preventing 
autoimmunity but also compromising effective anti-tumor immune responses (20, 180). DC 
utilize diverse mechanisms to mediate T cell tolerance including low expression of costimulatory 
molecules (100), expression of SOCS1/3 (181, 182), activation of regulatory T cells (Treg) (183), 
and production of immunosuppressive factors such as IL-10, TGFβ, IDO and retinoic acid (74, 
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76, 184, 185). Significant effort has been devoted to manipulating the phenotype and function of 
in vitro cultured DC used for vaccination (186), as well as to targeting Ag in vivo to specific DC 
populations (187). However, modulating and evaluating the ability of a vaccine to alter the 
phenotype of endogenous DC populations and the type of immune response they prime is still a 
significant challenge. Specifically, little data exist regarding the influence of the choice of 
vaccine Ag on the phenotype and function of endogenous DC. It has been well established that 
exogenous DC used for immunization are generally short-lived in the host after transfer (188), 
and that transfer of Ag from vaccine DC to endogenous DC is necessary for optimal CD4+ and 
CD8+ T cell responses (189, 190).  Therefore, understanding the impact of the choice of Ag, 
specifically the importance of its relative similarity to antigens against which the host is already 
tolerized, on endogenous DC warrants further study. Additionally, because gauging a vaccine’s 
efficacy often requires waiting several weeks to determine resultant antibody titers and vaccine-
induced T cell function, reliable, early signatures or biomarkers of both the endogenous DC 
response and the ensuing immune response would be of utility. 
We and others have previously shown that a long peptide (MUC1p) corresponding to five 
tandem repeats in the human tumor antigen MUC1 variable number of tandem repeats region is 
seen as a self-antigen by the human MUC1 transgenic mouse (MUC1.Tg), and that MUC1p 
vaccination results in hypo-responsiveness compared to a strong immune response in WT mice 
where MUC1p is a foreign antigen (Fig. 4) (4, 5, 191). This hypo-responsiveness results in the 
inability of the vaccinated mice to control growth of both transplantable and spontaneous tumors 
(175, 192).  Variations in vaccine design have resulted in some instances in a better immune 
response and better tumor control (5, 175), but they have been empirical, and without the full 
understanding of the underlying mechanism and early biomarkers of their efficacy, not readily 
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predictable. Now we show that the outcome of the MUC1p vaccine that currently requires 
several weeks after immunization to be evaluated can be predicted as early as 24h-72h post-
vaccination by the change in expression levels in DC of a group of catabolic enzymes, including 
trypsin, amylase, elastase, and carboxypeptidase B1, previously thought to be pancreas-restricted 
in expression.  These enzymes are significantly up-regulated in the splenic DC of WT mice 
following i.v. administration of the MUC1p vaccine, but not in MUC1.Tg mice. Failure to up-
regulate pancreatic enzyme expression was seen in the entire splenic DC population and was 
correlated with low co-stimulatory molecule expression, a decreased number of DC in the 
spleen, preferential priming of Foxp3+ Treg over IFNγ+ CD4+ T cells and impaired motility. 
Mechanistically, this DC phenotype was regulated by Treg and IL-10. The unexpected 
expression of pancreatic enzymes in DC and correlation with DC immunogenicity or 
tolerogenicity following vaccination provides a new early biomarker of vaccine efficacy.  
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Figure 4 Vaccination of MUC1.Tg mice with MUC1p results in an impaired adaptive immune response 
compared to WT. 
WT and MUC1.Tg mice were immunized s.c. with DC:MUC1p 1d after transfer of 5*106 CD4+ 
T cells from immunized WT donors (black bars) or PBS Ctrl (white bars). At 2 weeks post-
vaccination, LN and sera were pooled and tested for reactivity against MUC1p. (A and D) Re-
stimulation of lymphocytes recovered from immunized WT mice resulted in higher IFNγ 
production in both CD4+ and CD8+ compartments compared to MUC1.Tg mice. (B and E) 
Specific lysis of RMA-MUC1 tumor cells by pooled LN cells recovered from immunized WT 
and MUC1.Tg mice. (C and F) MUC1p-specific total IgG in the sera of immunized WT and 
MUC1.Tg mice. (G) 5*106 MUC1p-specific CD4+ T cells (VFT) were transferred i.v. into WT 
and MUC1.Tg recipients and mice were vaccinated with DC:MUC1p 1d later. After 4-5d, 
spleens were harvested and the percentage of VFT proliferation determined by gating on 
CFSEdimVα2+Thy1.1+CD4+ T cells.  Figures reprinted with permission from Turner, M.S. 
Journal of Immunology. 2007, and Ryan, S.O. Cancer Research. 2010. 
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2.3 RESULTS  
DC from MUC1p-immunized MUC1.Tg mice exhibit decreased expression of co-
stimulatory molecules, preferentially induce Foxp3+ Treg cells and have reduced motility  
 
Multiple factors contribute to or limit the ability of DC to prime T cells. These include the 
number of antigen-loaded DC (193), expression of co-stimulatory molecules on DC and 
production of stimulatory or suppressive cytokines (100), and the ability of DC to move to T cell 
areas within lymphoid tissue (194). We found that immunization of MUC1.Tg mice with 
MUC1p resulted in a decrease in the absolute number of CD11c+ cells in the spleen at 24h, while 
the same protocol in WT mice resulted in an increase in DC number (Fig. 6A). This decrease in 
DC number in MUC1.Tg mice also included a decrease in the absolute number of the DC used 
for immunization, as well as those from the endogenous DC compartment (Fig. 5). The same 
immunization also resulted in differential expression of co-stimulatory molecules, with 
significantly fewer DC from MUC1.Tg mice expressing CD40 and MHC II (Figs. 6B and 6C), as 
well as a reduction in the amount of CD86 expressed by those DC (Fig. 6D), relative to 
immunized WT mice.  
To examine the ability of DC that have been exposed to a self Ag induced environment to 
prime naïve CD4+ T cells, we again immunized WT and MUC1.Tg mice with MUC1p and 
isolated total splenic DC 24h post-immunization. The DC were immediately loaded with OVA 
and co-cultured with naïve, CFSE-labeled OT-II CD4+ T cells that recognize an I-A
b-restricted 
OVA peptide. After 7 days, T cells from those co-cultures were analyzed by flow cytometry. DC 
recovered from immunized MUC1.Tg mice primed a significantly higher percentage of Foxp3+ 
(Fig. 6E) and fewer IFNγ producing OT-II T cells compared to DC recovered from immunized  
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WT mice (Fig. 1F). DC can induce antigen-specific Treg proliferation (195) so we examined the 
relative proliferation of CD4+Foxp3+ Tregs. DC recovered from MUC1p vaccinated MUC1.Tg 
mice induced higher OT-II Treg proliferation compared to DC from MUC1p vaccinated WT 
animals (Figs. 6G and 6H).  
 
 
Figure 5 Fewer vaccine-derived DC are detectable in the spleen of immunized MUC1.Tg mice compared to 
WT. 
(A) WT and MUC1.Tg mice (n=2/group) were immunized with Cy3-labeled DC loaded with 
MUC1p (1*106 cells). 24h later, spleens were sectioned for confocal microscopy. Shown are 
representative images from immunized WT mice (I-WT), immunized MUC1.Tg (I-Tg), and a 
non-immunized control (Naïve-Tg). Magnification 20X. Images are representative of 5 sections 
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examined from 2 mice/group and 2 independent experiments. (B) Mice (n=3/group) were 
immunized as in (A) but with congenic, CD45.1+ DC. 
 
Figure 6 Immunization of MUC1.Tg mice with MUC1p results in decreased splenic DC number, 
costimulatory molecule expression, and preferential priming of Foxp3+ Treg. 
(A) WT and MUC1.Tg mice were immunized with unloaded DC (ctrl) or DC loaded with 
MUC1p. 24h post-immunization total splenic DC numbers were analyzed. Each symbol 
represents one mouse with bars showing mean ± SEM from three pooled independent 
experiments, with each experiment including 2-4 mice per group. (B-D) WT and MUC1.Tg mice 
were immunized as in (A). 48h post immunization bulk splenocytes were stained for FACS 
analysis. Data represent percentage of positive cells within the CD11c+ gate (B-C) or the MFI of 
cells within the CD11c+ gate (D). Symbols represent individual mice with bars showing mean ± 
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SEM and are representative of 2 independent experiments. (E-H) WT and MUC1.Tg mice were 
immunized as in (A). 24h later, splenic DC were bead isolated, loaded with OVA and co-
cultured with OT-II CD4 T cells for 7 days. On day 7, OT-II cells were treated with 
PMA/Ionomycin and analyzed by FACS. Each symbol represents an individual mouse with bars 
depicting mean ± SEM. Data are pooled from two independent experiments. (G) OT-II CD4+ T 
cells were labeled with CFSE and cultured as in (E-H). On day 7, CFSE dilution was assessed in 
CD4+Foxp3+ cells. Representative dot plots from MUC1p vaccinated WT and MUC1.Tg mice 
are shown (G). (H) Bars represent mean percentage proliferation ± SEM of OT-II CD4+Foxp3+ 
cells.  Data are representative of two independent experiments.  
 
While costimulatory molecule expression was decreased in DC recovered from mice that 
received immunization with self peptide, we found that immunization of MUC1.Tg mice with 
MUC1p surprisingly resulted in increased expression of CD74 (the MHC II invariant chain) in 
DC at 72h, compared to DC from MUC1p immunized WT mice (Fig. 7A). Previous studies have 
shown that expression of CD74 is inversely correlated to in vivo motility of DC (196). We 
purified splenic CD11c+ cells from WT and MUC1.Tg mice 72h post-MUC1p immunization and 
analyzed them immediately ex vivo using live cell microscopy. DC isolated from MUC1.Tg mice 
traveled shorter distances (Fig. 7B) and had smaller net displacements (Fig. 7C) than DC from 
WT.  
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Figure 7 Immunization of MUC1.Tg mice with MUC1p results in decreased DC motility. 
(A) WT and MUC1.Tg mice were vaccinated i.v. with DC loaded with MUC1p. RNA was 
extracted from pooled splenic DC 72h post vaccination for qRT-PCR. Bars represent mean ± 
SEM. Data are representative of three independent experiments. (B) and (C) WT and MUC1.Tg 
mice were vaccinated as in (A). 72h post immunization, splenic DC were bead isolated for live 
cell imaging. The track length (B) and displacement (C) were analyzed after 20h in culture. Each 
dot represents a single DC and bars depict mean ± SEM. Data are from two mice comparing 
6×103 DC per group.  
 
Differential expression in vivo of pancreatic enzymes in DC in response to vaccination with 
a foreign versus a self-antigen 
 
We were interested in comparing early (24h-72h) post-immunization events in the spleens of WT 
versus MUC1.Tg mice that might reveal one or more new mechanisms induced by the presence 
of a self-antigen that could mediate antigen-specific peripheral tolerance.  Accordingly, we 
immunized i.v. WT and MUC1.Tg mice with DC loaded with MUC1p as previously and 
conducted whole transcriptome analysis of total splenic RNA at 24h and 72h post-immunization.  
We identified 189 genes differentially expressed at both time points, with the most 
unexpected being a group of seven pancreatic catabolic enzymes and several of their isoforms 
that had not previously been reported to be expressed in lymphoid tissue (Table I). Significantly 
 40 
lower levels (between 10-80 fold) of transcripts for these enzymes were found in the total splenic 
RNA from MUC1p-vaccinated MUC1.Tg mice relative to WT mice 
 
Table 1 Immunization of MUC1.Tg mice with MUC1p suppresses expression of a cohort of “pancreatic” 
enzymes in the spleen. 
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Since the expression of each of these enzymes mimicked the entire cohort, we used 
trypsin 1 and carboxypeptidase B1 (CPB1) as representatives for more detailed analysis. qPCR 
analysis of total splenic RNA recapitulated the microarray data, showing a lack of up-regulation 
of trypsin and CPB1 transcript in spleens from MUC1.Tg mice post immunization with MUC1p 
relative to significant up-regulation in WT mice (Fig. 8A). Because there was little information 
about pancreatic enzymes in hematopoietic cells, we analyzed their baseline expression in 
different WT spleen cell populations: purified CD11c+ DC, T cells, bone marrow-derived 
macrophages (BMDM) and CD11c-depleted bulk splenocytes which included, among other cell 
types, B cells. CD11c+ DC expressed trypsin and CPB1 (Fig. 8B) as well as all the other 
enzymes identified in the gene array (not shown). BMDM expressed CPB1 but not trypsin, while 
purified T cells and CD11c depleted spleen cells were negative for both. Further dissection of the 
DC compartment into plasmacytoid DC, CD8α+ DC and CD8α- DC revealed that all DC 
subpopulations express these enzymes post vaccination while CD11c- cells do not (Fig. 9). 
Furthermore we show that these same pancreatic enzymes found in murine DC are also found in 
human monocyte-derived DC (Fig. 10).  
. 
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Figure 8 Immunization of WT but not MUC1.Tg mice with MUC1p results in up-regulation of pancreatic 
enzymes in splenic DC. 
 (A) WT and MUC1.Tg mice (n=3/group) were injected i.v with unloaded BMDC (ctrl) or 
BMDC loaded with MUC1 peptide (MUC1p). 24h later spleens were harvested, pooled 
according to group, and RNA extracted for qRT-PCR. Arbitrary Units were normalized to WT 
mice given the ctrl vaccine. Bars represent mean ± SEM. Data are representative of two 
independent experiments. (B) Splenic DC from unvaccinated mice were isolated with CD11c+ 
beads (n=3), total splenic T cells were isolated using negative selection via MACS depletion of 
CD3- cells, and BMDM (MΦ) were cultured for 8 days in the presence of L-cell supernatant as a 
source of M-CSF. RNA was isolated from all populations for qRT-PCR analysis. Units were 
normalized to expression levels in CD11c+ cells. Bars represent mean ± SEM. Data 
representative of two independent experiments. (C) WT and MUC1.Tg mice (n=3/group) were 
immunized as in (A). At 24h, splenic DC were isolated using CD11c+ beads for analysis by qRT-
PCR or Western blotting for trypsin and CPB1 (D). Bars represent mean ± SEM after 
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normalization to control vaccination. Data are representative of two (C) and three (D) 
independent experiments. (E) Mice were immunized i.v. with PBS (ctrl), Poly-ICLC (adj), or 
soluble MUC1p admixed with Poly-ICLC (MUC1p + Adj). 24h later spleens were harvested for 
qRT-PCR analysis. Bars represent mean ± SEM normalized to PBS control and are 
representative of four independent experiments. 
 
 
Figure 9 All major resident splenic DC subpopulations express higher levels of trypsin and CPB1 than 
CD11c- splenocytes. 
WT mice (n=3) were give 100µg of MUC1p admixed with 50µg poly:I-C in a total volume of 
100µL PBS via tail vein. 24 hours post injection, spleens were removed, pooled, and total splenic 
DC were bead isolated. DC were further separated via FACS into CD8α+ DC 
(CD11c+CD8α+B220-), CD8α- DC (CD11c+CD8α-B220-) and pDC (CD11c+ B220+). mRNA 
was extracted from these purified populations as well and DC depleted whole splenocytes and 
analyzed via qRT-PCR for trypsin and CPB1 expression. Bars represent mean ± SEM Data are 
representative of two independent experiments. 
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Figure 10 Human monocyte-derived DC upregulate elastase and CPB1 expression upon TLR3 stimulation. 
Peripheral blood mononuclear cells (PBMC) obtained from the leukopaks of healthy donors were 
cultured for 5 days in the presence of 100IU/mL of GM-CSF and 200IU/mL IL-4. Before 
culture, non-adherent lymphocytes (NonAdherent) were collected after failure to adhere to 
culture plastic after 1h and frozen for later analysis. On d5, immature DC were harvested, RNA 
extracted and qPCR conducted for elastase and CPB1. Remaining DC were matured overnight 
with 30μg/mL of Poly-ICLC and trypsin and CPB1 levels examined the following day to query 
differences in mDC. Data are representative of 2 independent experiments from 2 separate 
donors. 
 
Finally, we show that immunization with soluble MUC1p admixed with Poly-ICLC 
adjuvant (a TLR3 agonist) also led to up-regulation of trypsin and CPB1 in WT mice but not in 
MUC1.Tg mice (Fig. 8E). Adjuvant alone had no effect on these enzymes in either mouse strain. 
Thus the process is antigen dependent rather than delivery system or adjuvant dependent and it is 
regulated in all DC rather than only in the exogenous DC delivering the antigen.  
 45 
To show that differential regulation of these enzymes in WT and MUC1.Tg mice was 
driven by exposure to foreign versus self Ag rather than by a physiologic difference between WT 
and MUC1.Tg mice, we immunized MUC1.Tg mice with OVA, a foreign Ag in that mouse 
strain, and examined total and DC-specific splenic RNA 24h later. In contrast to MUC1p and 
control immunized mice, we found up-regulation of enzymes in the total splenic RNA and DC 
RNA of OVA immunized MUC1.Tg mice (Figs. 11A and 11B).   
 
Figure 11 Failure of DC to upregulate trypsin and CPB1 is recapitulated in the OVA model of self-tolerance. 
(A) MUC1.Tg mice (n=3/group) were immunized i.v. with PBS (ctrl), soluble MUC1p or 
ovalbumin (OVA) admixed with Poly:ICLC. Spleens were harvested at 24h post immunization 
and pooled for qRT-PCR analysis. Bars represent mean ± SEM normalized to PBS control. Data 
are representative of three independent experiments. (B) MUC1.Tg mice (n=3/group) were 
immunized i.v. with unloaded DC (ctrl) or DC loaded with OVA (OVA). 24h post-immunization 
splenic DC were MACS purified for qRT-PCR analysis. Bars represent mean ± SEM normalized 
to ctrl. Data are representative of three independent experiments. (C) RIP.OVA mice 
(n=3/group)  were immunized and processed as in (B).  Bars represent mean ± SEM normalized 
to ctrl vaccination. Data are representative of two independent experiments. 
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We also wanted to show this regulation by a self Ag in another model of self-tolerance to 
be certain that it was not unique to the MUC1.Tg strain or MUC1p as Ag. We immunized 
RIP.OVA mice, which express the ovalbumin gene under transcriptional control of the rat insulin 
promoter and are tolerant to OVA protein (197), with DC loaded with OVA.  The DC recovered 
from these mice also failed to up-regulate trypsin and CPB1 (Fig. 11C).  
 
Regulation of expression of pancreatic enzymes in DC is dependent on CD4+ regulatory T 
cells 
 
Given the antigen specificity of Treg and their ability to modulate DC phenotype and function 
(48, 198), we hypothesized that the differential expression of pancreatic enzymes in DC might 
mark DC that had been acted upon by Treg. We cultured BMDC with bead isolated CD4+ Teff 
and/or Treg, polyclonally activated with anti-CD3 and anti-CD28 antibodies. After 24 hours of 
co-culture, we found that DC up-regulated trypsin and CPB1 in the presence of activated Teff, 
but not in the presence of Treg. Importantly, simultaneous culture of DC with Teff and Treg also 
resulted in low levels of trypsin and CPB1 in DC, demonstrating that Treg actively suppress the 
ability of Teff to induce enzyme up-regulation. LPS alone had no effect on enzyme levels. (Fig. 
12A) 
To determine if Treg played a similar role in vivo, MUC1.Tg mice were depleted of Treg 
by injection of anti-CD25 antibody and subsequently vaccinated with soluble MUC1p admixed 
with Poly-ICLC adjuvant. In control Treg competent mice, we observed the anticipated DC 
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phenotype with suppressed enzyme expression, while DC from immunized Treg-depleted 
MUC1.Tg mice up-regulated the enzymes (Fig. 12B).  
 
 
 
 
Figure 12  Interactions between DC and CD4+ T cells control expression levels of pancreatic enzymes in DC. 
(A) DC were cultured alone (ctrl), with LPS, or with polyclonally activated CD25-CD4+ T cells 
(Teff) and/or CD25 +CD4 + T cells (Treg). After 24h of co-culture DC were separated and 
mRNA was extracted for qRT-PCR analysis. Units were standardized against levels pre-culture 
(baseline). Bars represent mean ± SEM. Data are representative of two independent experiments. 
(B) MUC1.Tg mice were treated with an antibody against CD25 to deplete regulatory CD4 T 
cells (Anti-CD25) or with an isotype control (ctrl). 2 days following depletion, mice were 
vaccinated with soluble MUC1p plus Poly-ICLC i.v. Splenic RNA was extracted 24h post 
vaccination for qRT-PCR analysis. Units were standardized against isotype control treated mice. 
Bars represent mean ± SEM respectively. Data are representative of 3 independent experiments. 
 
 48 
IL-10 is required in vivo for suppression of pancreatic enzyme expression in DC 
 
One of the few transcripts in the gene array data that was higher at 24 hours post vaccination in 
MUC1.Tg mice compared to WT mice was IL-10 (not shown).  To confirm, we vaccinated mice 
with soluble MUC1p admixed with Poly-ICLC and saw a dramatic increase in IL-10 transcript 
levels (Fig. 13A). Given the known ability of IL-10 to modulate DC phenotype and function in 
the direction of tolerance versus immunogenicity (199), we hypothesized that it might also be 
participating in the suppression of DC pancreatic enzyme levels. Accordingly, we treated 
MUC1.Tg and WT mice with an antibody against the IL-10 receptor (IL-10R) prior to 
vaccination with MUC1p (Fig. 13B). Blockade of the IL-10R in vivo resulted in DCs that had 
equal levels of pancreatic enzymes in both WT and MUC1.Tg mice in response to MUC1p 
vaccination. In support of the suppressive effect of IL-10 on DC enzyme expression, we 
immunized IL-10-/- mice crossed onto the MUC1.Tg background (MUC1/IL10-/-) with MUC1p. 
Immunization in the absence of IL-10 also resulted in the reconstitution of trypsin, CPB1, and 
elastase expression in DC (Fig. 13C). 
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Figure 13 IL-10 is required in vivo for control of trypsin, CPB1, and elastase expression in DC 
(A) MUC1.Tg (n=3) mice were immunized with PBS (ctrl) or soluble MUC1p admixed with 
Poly-ICLC (MUC1p). IL-10 expression was measured by qRT-PCR on total splenic mRNA 24h 
post vaccination. Bars represent mean ± SEM. Data are representative of at least 4 independent 
experiments. (B) WT and MUC1.Tg mice were treated with an IL-10R blocking antibody 
followed by i.v. immunization with PBS (ctrl) or MUC1p as in (A). 24h post vaccination splenic 
RNA was extracted for qRT-PCR analysis. Units were normalized to WT ctrl. Bars represent 
mean ± SEM. Data are representative of two independent experiments. (C) WT, MUC1.Tg and 
MUC1+/+IL-10-/- (n=3/group) mice were immunized with DC:MUC1p (100:WT, 100:MUC1.Tg, 
and 100:MUC1/IL-10-/-). After 24h, splenic DC were isolated and the relative amounts of 
trypsin, CPB1, and elastase were measured by qRT-PCR. Bars represent mean ± SEM. Data are 
representative of 3 independent experiments. 
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2.4 DISCUSSION 
Our data reveal the presence of a new pancreatic enzyme signature in DC that may be predictive 
very early post -vaccination (24-72h) of downstream antigen-specific T cell responses. The 
enzymes comprising this signature (e.g., trypsin, CPB1, elastase) have well-characterized 
functions in the pancreas but have not been previously reported in DC. Differential expression of 
these enzymes in DC following immunization with a self or a foreign Ag was associated with 
dramatic changes in the immunogenicity of the endogenous splenic DC compartment. A number 
of other peptidases utilized by DC, especially in the context of antigen processing and 
presentation, have been characterized (89) and an expanding repertoire of enzymes involved in 
generating MHCI-restricted peptides is beginning to be elucidated (86). None of them, however, 
fall into the category of pancreatic enzymes. Our interest in these enzymes was generated by the 
observation that their expression levels seen in total spleen gene array were differentially 
regulated in response to immunization with a self versus a foreign antigen. They are up-regulated 
following exposure to a foreign antigen (e.g., MUC1p in WT mice) and suppressed following 
exposure to a self-antigen (e.g., MUC1p in MUC1.Tg mice).  Importantly, the signature of 
pancreatic enzyme expression by DC is not dependent on whether the antigen is also a tumor 
antigen. Our data show that immunization of RIP.OVA mice with OVA results in a similar 
failure to up-regulate DC enzymes while vaccination of MUC1.Tg mice induces up-regulation, 
suggesting that this is a general marker corresponding to the maintenance of self-tolerance rather 
than a unique characteristic of MUC1-specific immunity. As early as 24h post vaccination and 
until at least 72h, the differential expression pattern of these enzymes was observed in the total 
CD11c+ splenic compartment.  This was independent of whether antigen was presented on 
exogenous DC that had taken up and processed the peptide prior to immunization, or as soluble 
 51 
antigen plus adjuvant. This illustrates the fact that both the initial DC presenting the antigen as 
well as all other DC in the spleen that either gained access to the antigen or were subject to 
microenvironmental changes, such as increased IL-10 initiated by the antigen, were suppressed 
presumably in order to not propagate anti-self responses. 
Our data suggest that a DC presenting a self-antigen is rapidly affected by interactions 
with pre-existing Treg specific for that antigen, as depletion of Treg restores antigen-specific up-
regulation of pancreatic enzymes. A large number and repertoire of MUC1p-specific Tregs could 
arise from thymic expression of MUC1 in MUC1.Tg mice (28), or through prior exposure to 
antigen in a sub-immunogenic setting. We also show that IL-10 is an important soluble 
regulatory mediator that is likely elicited either directly or indirectly by Treg upon encounter 
with self-antigen on DC and is involved in the suppression of pancreatic enzyme expression in 
addition to its well-characterized effects on DC stimulatory capacity and CD80/86 and MHCII 
expression (200-202)  
The most stimulating question is how are the vast majority of splenic DC (and potentially 
all) simultaneously either prevented from or stimulated to induce an immune response, the 
surrogate marker of which is up-regulation or lack of expression of pancreatic enzymes. At least 
two possibilities in addition to diffusion of IL-10 and/or other cytokines exist: 1) highly efficient 
Ag distribution throughout the spleen such that many DC are presenting self Ag and are 
therefore individually affected by the action of Treg or T effector cells, and/or 2) highly effective 
signal transduction to all other DC in the organ from a rare DC that is presenting the antigen and 
has been affected by Treg or T effector cell.  There is support in the literature for both 
mechanisms (203, 204). 
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The term “infectious tolerance” has been applied to the process by which one population 
of leukocytes transfers tolerance to another. In most instances, this involves Treg suppression of 
T effector cell generation either through a direct contact or through elaboration of regulatory 
factors (205). Tolerogenic DC have also been implicated because of their ability to promote the 
generation of iTreg (206, 207). Most of the studies showing these interactions have been 
performed in vitro and although similar regulation has been postulated in vivo, most data in 
support of it have been generated by pharmacologic manipulations of the system (135). We 
suggest that our results provide evidence that infectious tolerance occurs in vivo. We propose a 
two-step model of infectious tolerance. The first step is a signal to all DC in the lymphoid organ, 
and presumably other tissues where self-antigens can be processed and presented by DC, to 
prevent the up-regulation of pancreatic enzymes. This step is immediate and is initiated by the 
first encounter of a self-antigen-presenting DC and a cognate Treg. The earliest time point we 
studied was 24h post-vaccination when expression of the enzyme cohort was already suppressed. 
However, we suspect that the signal is sent much earlier depending on the route of antigen 
delivery. With an exogenous DC-based vaccine, the antigen is already processed when the DC 
enters a lymphoid organ such as spleen, and the suppression signal from Treg may be very 
quickly generated and propagated.  In the case of a soluble antigen entering a lymphoid organ, 
there is likely a minor delay in suppression due to the time it takes for resident DC to take up, 
process and present the antigen. The second step is delayed and involves the conversion of the 
DC into a phenotypically and functionally tolerogenic cell that primarily supports generation of 
Treg. We show that DC recovered from spleens exposed to self Ag through vaccination 
expressed low levels of costimulatory molecules and had reduced motility, likely resulting in less 
efficient traffic into T cell zones, and primed the expansion of more Treg than Teff cells when 
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cultured with antigen specific T cells. In vivo, this would assure that self-antigen specific Treg 
continue to be primed for the duration of antigen exposure, which would likely protect the host 
from autoimmunity in non-pathologic conditions, but may also be responsible for preventing 
effective anti-tumor immunity.  
We are reporting a new observation that will require further studies to fully elucidate the 
exact mechanism involved, especially at the level of the regulated DC. We do not know the exact 
role of pancreatic enzymes in DC, whether they are involved in antigen processing or other DC-
intrinsic functions. Nor can we yet postulate how their expression is coordinately regulated. 
However, the expression levels of trypsin and CPB1 provide an early readout of the effects of 
self or foreign Ag on the phenotype and function of endogenous splenic DC.  The microarray 
data did not reveal any candidate transcription factors that are differentially expressed in the 
regulated DC that could be responsible for this enzyme cohort’s transcriptional control. We 
expect that the 24-hour time point may have been too late for identifying such factor(s). Now 
that our attention is focused specifically on these enzymes and DC, we will look at much earlier 
time points.  We also have not yet fully explored the role of IL-10 and the precise signals it 
provides to the DC and how those signals relate to enzyme suppression, or other effects on DC 
phenotype.  
We expect that immune hypo-responsiveness reported to vaccines based on many other 
tumor associated antigens (208, 209) could also be explained by how similar or different they are 
from those same antigens expressed on normal cells. The ability of immunization with self-
antigens other than MUC1p to tolerize endogenous splenic DC remains to be tested. However, 
the conservation of enzyme expression patterns between immunizations using different self-
antigens leads us to envision a similar conservation in the resultant DC phenotype. Therefore, 
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pancreatic enzyme expression in DC represents a new finding and suggests an easily accessible 
signature that can be used to assess almost immediately the suitability of a particular antigen and 
the effect of a particular immune manipulation designed to either induce tolerance or immunity. 
This can be particularly helpful in animal models where various immunotherapeutic approaches 
are being tested and multiple approaches compared.  Time could be saved and animals spared if 
the final outcome (e.g. tissue graft acceptance or a tumor rejection) were not the primary, and to 
date the main endpoints by which the success of the immune manipulation could be evaluated.     
Our specific interest is the response to a tumor antigen vaccine and determining how best 
to evaluate and compare efficacy early after vaccination, rather than waiting for the results of a 
tumor challenge in an animal or tumor recurrence in a patient. Previous work has shown that 
various MUC1p-based vaccines can fail to eradicate or slow the growth of MUC1+ tumors in 
MUC1.Tg mice while remaining effective in WT mice where MUC1p is a foreign antigen (175, 
192). Vaccine-induced control of tumor growth is dependent on CD4+ T cells which are not fully 
functional in immunized MUC1.Tg mice compared to WT (191) (4). This study provides 
evidence that the defect in anti-tumor immunity in MUC1.Tg mice is attributable in part to 
splenic DC preferentially priming CD4+ T cells into Foxp3+ Treg versus IFNγ+ cells likely via 
low costimulatory molecule expression and impaired motility.  
Our previous studies have emphasized the importance of antigen selection, especially in 
the case of non-viral tumor associated antigens (151). This study confirms the importance of 
proper antigen selection that in some cases may outweigh the importance of adjuvants or 
delivery systems. Among the many tumor associated antigens that have been fully characterized 
(210), it should be possible to focus on those that are less self and more foreign due to many 
differences in their post-translational modifications between normal and tumor cells.  As we have 
 55 
shown previously, a tumor-specific sugar added to MUC1p to create TnMUC1 results in strong 
immunogenicity rather than tolerance in immunized MUC1.Tg mice (211). The wrong antigen or 
the wrong epitope, on the other hand, leads to DC suppression, infectious tolerance, and further 
promotion of Treg generation that not only fails to achieve an effective antitumor immune 
response, but may actually promote tumor growth by selectively expanding tumor-antigen-
specific Treg (212). Depletion of Treg with anti-CD25 antibodies or diphtheria toxin have shown 
a good deal of promise in preclinical models of cancer immunotherapy (213-217). IL-10R 
blockade has also been shown to improve overall vaccine responses in several models, while IL-
10 production, specifically by CD4+CD25+ Treg is negatively correlated with vaccine success 
(155, 218). We propose that these treatments work because they prevent DC-propagated 
infectious tolerance. 
2.5 MATERIALS AND METHODS 
Mice 
C57BL/6, RIP.OVA, and OT-II mice were purchased from the Jackson Laboratory. MUC1.Tg 
mice were purchased from Dr. Sandra Gendler (Mayo Clinic) (219) and/or bred in the University 
of Pittsburgh animal facility. VFT mice were generated at the University of Pittsburgh 
Transgenic Mouse Facility. All colonies were subsequently bred and maintained at the 
University of Pittsburgh under specific pathogen free conditions. Experiments were approved by 
the Institutional Animal Care and Use Committee of the University of Pittsburgh.  
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Peptides 
A 100mer MUC1 peptide (MUC1p) represents 5 repeats of the 20- amino-acid sequence 
HGVTSAPDTRPAPGSTAPPA from the MUC1 VNTR region. It was synthesized as described 
previously (4) by the University of Pittsburgh Genomics and Proteomics Core Laboratories. 
OVA323-339 peptide and ovalbumin protein were purchased from Sigma. 
 
Mouse DC culture and vaccines 
BMDC were generated according to established protocol (5). Briefly, female C57BL/6 mice 
(Jackson) were sacrificed and their femurs and tibiae removed. Marrow was flushed with RPMI 
(2% FCS, 1% Penn-Strep and 2-ME). Cells were passed through a 70μM strainer and pelleted 
before RBC lysis using ACK buffer. Cells were resuspended in AIM-V (Gibco), counted and 
plated at 1.5-2×106/mL in AIM-V containing 10-20ng/mL GM-CSF (Miltenyi). On d3 and d5 
half the media was replaced with fresh AIM-V and GM-CSF. On d6 of culture, DC were 
harvested with 2mM EDTA, counted and (when indicated) loaded with either 30μg/mL MUC1 
100mer or 100μg/mL ovalbumin and matured with 25ug/mL of Poly-ICLC (Hiltonol), a 
generous gift from Oncovir, overnight. On d7, cells were harvested as above. For immunizations, 
d7 DC were washed and resuspended in sterile PBS. Mice were immunized i.v. via the lateral tail 
vein with .5-1×106 DC. Soluble peptide immunizations consisted 100μg of MUC1 100mer 
peptide or ovalbumin and 50μg of Poly-ICLC in 100μL of PBS.  
 
Microarray 
Whole spleen from WT and MUC1.Tg mice (n=3/group) was harvested at 24h and 72h post-
immunization with DC loaded with MUC1 100mer peptide. RNA extraction was performed 
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using Trizol (Invitrogen). RNA from mice within groups was pooled followed by hybridization 
onto Illumina WG6 arrays. Data analysis was conducted by the University of Pittsburgh GPCL 
Bioinformatics Core facility using the Efficiency Analysis method of identifying differentially 
expressed genes (220). Microarray data have been deposited in the NCBI Gene Expression 
Omnibus (GEO) with the accession number GSE43503 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE43503). 
 
PCR and qRT-PCR 
RNA was isolated from splenic tissue or CD11c+ bead isolated (Miltenyi) splenocytes using 
either an RNeasy mini kit (Qiagen) or Trizol (Invitrogen) according to manufacturer’s protocol). 
RT-PCR was performed using Oligo(dT) primers and  SuperScript III reverse transcriptase 
(Invitrogen). cDNA was amplified using the following primers: trypsin (forward 1: 5’-
GGCCCTTGTGGGAGCTGCTG-3’; reverse 1: 5’-GCAGGTGCACAGGAGCTGGG-3’; 
forward 2: 5’-GCTCTGCCCAGCTCCTGTGCACCT-3’; reverse 2: 5’- 
TCAGCCTGAGGCAGCAGTGGGGCAT-3’), CPB1 (forward 1: 5’-
TGGTGAGTGTGGCCCTGGCT-3’; reverse 1: 5’-TCCACTTGCACGGGTGTGGC-3’ forward 
2: 5’- GCCCTGGTGAAAGGTGCAGCAAAGG -3’; reverse 2: 5’- 
AGCCCAGTCGTCAGATCCCCCAGCA -3’), Elastase (forward: 5’-
TTCCGGAAACTGACGCCCGC-3’; reverse: 5’-TGGGCCAGCTCCCCATTGGT-3’), GAPDH 
( forward 1: 5’-TTGGCCGTATTGGGCGCCTG-3’; reverse 2: 5’-
TCTCCAGGCGGCACGTCAGA-3’; forward 2: 5’- AGACGGCCGCATCTTCTTGTGCAGT-
3’; reverse 2: 5’- TGGTGACCAGGCGCCCAATACGGC-3’), and IL-10 (forward: 5’- 
CTTCCCAGTCGGCCAGAGCCA-3’; reverse: 5’- CTCAGCCGCATCCTGAGGGTCT-3’). 
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qPCR was done using a QuantiTect SYBR Green PCR kit (Qiagen) according to the 
manufacturer’s protocol. Reactions were run on a StepOne Plus instrument (Applied Biosystems) 
and data was generated using the ΔCT method (221).  
 
Western blotting 
Cells were lysed and run on a 10% Tris-HCL Mini-PROTEAN TGX precast gel (BioRad), 
followed by transfer onto a PVDF membrane. After blocking for 1hr in 5% milk, the membrane 
was incubated with one of the following antibodies: Rb X-CPB1 (M-134), Rb X-trypsin (M-60) 
(both Santa Cruz) or β-Actin (AC-74, Sigma). Blots were then incubated with the appropriate 
HRP-conjugated secondary antibodies (Santa Cruz) and developed using SuperSignal West 
chemiluminescent substrate (Pierce) before imaging on a Kodak Image Station 4000MM. 
 
DC/T cell co-cultures 
CD4 effector and regulatory T cells were isolated from C57Bl/6 mouse splenocytes using the 
CD4+CD25+ Regulatory T cell Isolation Kit (Miltenyi) and preactivated overnight with 1µg/ml 
plate-bound anti-CD3 and .5µg/ml soluble anti CD28.  Bone marrow derived dendritic cells 
(BMDC) were generated using above described procedure used to culture vaccine DC. On day 6, 
semi-adherent cells, which represent semi-mature dendritic cells, were removed by gentle 
agitation. DC were added to preexisting T cell cultures at DC:T cell ratios of 2: 5, except when 
both regulatory and effector T cells were added, in which case the ratio was 2:5:5. Where 
indicated, LPS was added to the culture along with the DC at a final concentration of 1ng/mL. At 
24 hours post co-culture, DC were isolated based on plate adherence and RNA was extracted and 
analyzed as described 
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Depleting and/or blocking antibody experiments 
All antibodies were purchased from Bio-X-Cell.  Mice received an i.p. injection containing 
200µg of an anti CD25 antibody (clone PC-61.5.3) to deplete CD4+ regulatory T cell. 6 days 
following this treatment, mice were vaccinated as described and sacrificed 24 hours following 
vaccination. In the case of IL-10R blockade, mice were given 250µg of an anti-IL-10R antibody 
(clone 1B1.3A), IP. These mice were then vaccinated as described at 48-72 hours post antibody 
treatment along with an additional dose of 250µg of anti IL-10R antibody. Mice were sacrificed 
24 hours following vaccination and second antibody dosing. An equal concentration and volume 
of Rat IgG1 specific for horseradish peroxidase (HRPN) was injected as a control for the 
depleting/blocking antibodies where indicated. 
 
Flow cytometry 
Anti-CD11c-PacificBlue, anti-CD80-FITC, anti-CD3-PerCP, anti-CD25-PE  (BD Bioscience), 
anti-I-Ab-PeCy7, anti-CD40-APC, anti-CD86-PerCP, anti-Foxp3-PacificBlue (BioLegend), anti-
IFNγ-APC, and anti-CD4-FITC (eBioscience) antibodies were used. Cells were analyzed on an 
LSR II (BD) and data were analyzed using FacsDiva software (BD).  
 
Ex vivo motility assay 
Pooled splenocytes were recovered from MUC1p- immunized WT and MUC1.Tg mice 48h post-
immunization (n=2/group). DC were isolated with CD11c beads (Miltenyi) and plated at 2×105 
cells into Poly-D-Lysine coated 35mm dishes (MatTek). Cells were labeled according to 
protocol with Cell Tracker Red (Invitrogen) and imaged at 10X in DIC and TRITC channels on a 
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Nikon Eclipse live cell system at 5min intervals for 24h. Motility was analyzed using the Imaris 
Track algorithm in Imaris (Bitplane). 
 
Statistics 
Data show mean ± the standard error of the mean (SEM). Statistical significance between groups 
was defined as p≤.05 using an unpaired, 2-tailed Student’s t test (GraphPad Prism). 
 
Human DC Culture  
Peripheral blood mononuclear cells (PBMC) obtained from the leukopaks of healthy donors were 
cultured for 5 days in the presence of 100U/mL of GM-CSF and 200U/mL IL-4. On d5, 
immature DC were harvested, RNA extracted and qPCR conducted for trypsin and CPB1. 
Remaining DC were matured overnight with 30μg/mL of Poly-I:C, and trypsin and CPB1 levels 
examined the following day to query differences in mDC. 
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3.0  NOVEL MECHANISMS UNDERLYING THE IMMEDIATE AND TRANSIENT 
GLOBAL TOLERIZATION OF SPLENIC DC FOLLOWING VACCINATION WITH A 
SELF-ANTIGEN 
3.1 ABSTRACT 
Dendritic cells (DC) are potent directors of the immune response. As such, vaccines designed to 
elicit immunity against pathogens and tumors rely on DC directly or indirectly. However, the 
role of endogenous DC in mediating vaccine-induced tolerance and immunity is unclear. Using 
the tumor antigen MUC1 as a relevant self-antigen, we previously showed that i.v. immunization 
of MUC1.Tg mice, but not WT, with MUC1 resulted in a tolerized splenic DC compartment 
marked by low costimulatory molecule expression, induction of regulatory T cells (Treg), and 
suppressed expression of trypsin and Carboxypeptidase B1 (CPB1). Here we examined the 
functional phenotype underlying these tolerized DC. We found that immunization with self-
antigen results in an endogenous, splenic DC population that shares some characteristics with 
immature DC such as a less inflammatory cytokine/chemokine profile, deficient activation of 
NFκB, and sustained expression of zDC and CCR2. However, these tolerized splenic DC 
concurrently acquire novel attributes in response to exposure to self antigen, including the 
inducible expression of Aldh1/2 and phospho-STAT3. We also found that suppressed expression 
of trypsin impedes the ability of DC to degrade extracellular matrix protein, while 
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metallopeptidases including CPB1 are required by DC to induce optimal, antigen-specific CD4+ 
T cell proliferation. DC were not refractory to maturation after stimulation with a TLR3 agonist, 
illustrating that this tolerized state is not terminal, and these DC are capable of inducing 
immunity to foreign antigen after exposure to self antigen as been cleared.   
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3.2 INTRODUCTION 
Dendritic cells (DC) can induce potent immunity by presenting foreign antigens (Ag) derived 
from infectious agents or abnormal self antigens derived from tumors (222). However, DC can 
also maintain tolerance to self Ag derived from healthy tissues, environmental agents, and 
commensal microbiota (76, 100). Ablation of DC during homeostasis results in a breakdown of 
CD4+ T cell tolerance with ensuing fatal autoimmunity (119, 179). Multiple mechanisms assist 
DC in maintaining peripheral tolerance to self Ag, such as low expression of costimulatory 
molecules such as MHC II, CD40, CD80, and CD86, production of anti-inflammatory molecules 
such as IL-10, IDO, and retinoic acid (RA), exposure to low Ag dose, and expression of cell 
surface molecules such as DEC-205 and CD103 that mark DC that preferentially prime 
peripheral regulatory T cells (Treg) (75, 76, 100, 103, 105). Vaccines designed to induce 
immunity against tumors often utilize antigens that are closely related to self-antigens, or are a 
combination of normal (self) and abnormal (foreign) epitopes, resulting in a less robust immune 
response (223). Immune responses to vaccines are controlled by many different mechanisms in 
the periphery. Better understanding of these mechanisms is important for designing vaccines that 
elicit the desired outcome: strong, protective immunity against pathogens and cancer, or 
tolerance for self antigens to avoid autoimmunity. 
We have been studying immune responses to cancer vaccines based on peptides derived 
from the human tumor antigen MUC1 that range from those closest to self (i.e. peptides with no 
sugar moieties), to those representing “abnormal self” (i.e. peptides decorated with tumor-
specific, O-linked GalNAc adducts) (5, 224). We recently published that i.v. immunization of 
human MUC1.Tg mice (MUC1.Tg) with an unglycosylated MUC1 peptide (MUC1p) resulted in 
the transient tolerization (between 24h-72h) of the entire splenic DC population that failed to 
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upregulate costimulatory molecules, lacked motility, and preferentially primed Foxp3+  Treg. 
These vaccine-induced, tolerized DC also differed in their gene expression profile from 
immunogenic DC by suppressed expression of a group of “pancreatic” enzymes, specifically 
trypsin and carboxypeptidase B1 (CPB1) (6), which we proposed as being predictive biomarkers 
of vaccine outcome . These results were consistent with the previously observed low level of 
vaccine-induced immunity against MUC1p in MUC1.Tg mice (4, 5, 173).   
In the current study we elucidated several molecular and cellular pathways that 
characterize DC tolerized by vaccination with a self antigen . We show that, in contrast to 
endogenous splenic DC recovered from mice vaccinated with a foreign antigen, splenic DC from 
mice vaccinated with self-antigen inhibit NFκΒ while simultaneously increasing signaling 
through phospho-STAT3. As a result, they produce fewer inflammatory cytokines and 
chemokines. These DC also induce expression of aldehyde dehydrogenase 1 (Aldh1), the 
enzyme catalyzing the last step in the biosynthesis of immunosuppressive retinoic acid (RA), 
suggesting a novel role for RA in promoting this vaccine-mediated DC tolerance.  
We also examined the functional consequence of the previously reported suppressed 
expression of “pancreatic” proteases in tolerized DC that are highly upregulated in immunogenic 
DC.  We show that increased expression by DC of metallopeptidases, such as CBP1, is required 
for optimal proliferation of MUC1p-specific CD4+ T cells, suggesting their role in increasing 
efficiency of antigen processing and presentation. We found that trypsin expression, on the other 
hand, is required for degradation of the extracellular matrix (ECM), facilitating DC motility. 
Suppressed expression of these enzymes in tolerized DC contributes to their low T cell 
stimulatory capacity and low motility, resulting in low or no response to a self- antigen vaccine.  
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3.3 RESULTS 
Immunization with a self-antigen promotes non-inflammatory DC with decreased 
chemotactic potential and a novel transcriptional signature 
 
As we previously reported, splenic DC recovered from MUC1.Tg mice immunized i.v. with 
MUC1p express lower levels of MHC II, CD40, and CD86, compared to DC from WT mice 
immunized with the same peptide. They also preferentially prime naïve CD4+ T cells into Treg 
versus IFNγ-producing effector T cells. Additionally, there are fewer DC 24h post-immunization 
in the spleens of MUC1.Tg mice compared to WT (6). Low costimulatory molecule expression 
and priming of Treg are hallmarks of an immature DC (iDC) (100, 225, 226). We now show, 
using a cytokine blot array, that DC recovered from MUC1p-immunized MUC1.Tg mice 
produce lower levels of pro-inflammatory cytokines (i.e., IL-1a, TNFa, IL-6) relative to WT 
(Figs. 14A and 14B). These tolerized DC also produced less lymphotactic chemokines such as 
MIP-1b, RANTES, and IL-16 as well as less CXCL1, MIP-2, and CCL2. Tolerized DC failed to 
down-regulate expression of CCR2, the receptor for CCL2, and a phenotypic marker of iDC 
(227, 228) (Fig. 14C). This CCR2 was functional as evidenced by the ability of more tolerized 
DC to directionally migrate towards a linear CCL2 gradient compared to DC from immunized 
WT mice (Fig. 15). 
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Figure 14 DC recovered from MUC1p-immunized MUC1.Tg mice are less inflammatory than DC from 
immunized WT mice. 
(A) WT and MUC1.Tg mice (n=3/group) were immunized (i.v.) with DC:MUC1p (MUC1p) 
(1×106 cells). 1d later isolated splenic DC were cultured overnight in the presence of 500ng/mL 
LPS and Brefeldin A. DC lysates were then incubated on a mouse cytokine blot array and 
developed according to the manufacturer instructions.  Blots are shown in (A) and are 
representative of 2 independent experiments. (B) Densitometry of the blots from (A) quantified 
with Image J. (C) Mice were immunized with MUC1p as in (A) with splenic DC isolated at 24h 
and qPCR performed for CCR2. Data are normalized to MUC1p-immunized WT mice, with bars 
representing the mean± SEM. Data are representative of 3 independent experiments.  
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Figure 15  Splenic DC isolated from immunized MUC1.Tg mice express functional CCR2 
Mice (n=3/group)  were immunized as in Fig. 14 and DC isolated at 24h and plated onto 
chemotaxis slides ± 50ng/mL linear gradient of recombinant CCL2. Cells were imaged for 4h 
and the cells with directional migration quantified from 5 fields/group. Data are representative of 
2 independent experiments. 
 
Suppressor of cytokine signaling 3 (SOCS3) and histone deacetylase 11 (HDAC11) have 
been implicated in suppressing pro-inflammatory cytokine production and promoting IL-10 
expression respectively in DC (122, 182). While SOCS3 expression was decreased by 
approximately 50% in DC recovered from MUC1p vaccinated WT mice, as would be expected 
of a DC developing an immunostimulatory phenotype, its expression was unchanged in DC from 
immunized MUC1.Tg mice (Fig. 16A). HDAC11 levels in immunized WT or MUC1.Tg mice 
were not significantly different (Fig. 16B). This suggested that these two transcription factors, 
which play a role in DC that are actively immunosuppressive, do not have the same role in either 
inducing or maintaining the transient tolerized state of DC from vaccinated MUC1.Tg mice. We 
also examined the transcription factor Zbtb46 (zDC) that has recently been identified as a 
conventional DC-lineage marker whose expression is inversely correlated with DC maturational 
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status (119, 120, 229). Expression of zDC was approximately 2.5-fold higher in tolerized DC 
recovered from immunized MUC1.Tg mice compared to WT (Fig. 16C). Expression of zDC and  
CCR2 decreased after stimulation of DC with Poly:ICLC ex vivo demonstrating that these DC 
are not refractory to maturation.  (Figs. 16C and 16D).   
 
Figure 16 SOCS3 and HDAC11 do not contribute to vaccine-tolerized DC while sustained expression of 
Zbtb46 and CCR2 maintain an immature DC phenotype 
WT and MUC1.Tg mice (n=3/group) were immunized (i.v.) with DC:MUC1p (MUC1p) (1×106 
cells) or unloaded DC (Ctrl). 1d later, isolated DC were pooled for qRT-PCR for SOCS3 (A) or 
HDAC11 (B). (C and D) Mice were immunized with MUC1p as in (A) with splenic DC isolated 
at 24h and qRT-PCR for zDC (C) or CCR2 (D) conducted with (Poly:ICLC) or without (No Tx) 
stimulation with 30ug/mL of Poly:ICLC for 4h. Bars represent mean± SEM after normalization 
to respective control vaccinations and are representative of 3 independent experiments 
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Increase in phospho-STAT3 and decrease in NFκΒ p65 in tolerized DC 
Activation of STAT3 characterizes DC that are unable to prime efficient Th1 responses, and is 
considered a negative regulator of DC function (123, 230). Splenic DC isolated from MUC1p 
immunized MUC1.Tg mice upregulated phospho-STAT3 24h post-immunization (Fig. 17A). 
Conversely, NFκΒ pathway activation resulting in degradation of IκΒα and phosphorylation of 
p65, is critical for DC phenotypic maturation and immunogenic function (118, 231).  As shown 
in Figs. 17B and 17C, tolerized DC from immunized MUC1.Tg mice express less phospho-p65 
with a concurrent increase in total IκΒα. Therefore, the low immunogenicity of tolerized DC is 
due, in part, to deficient activation of NFκβ signaling and self-antigen-induced STAT3 signaling.  
 
 
Figure 17 Deficient NFκΒ activation and enhanced STAT3 signaling in vaccine-tolerized DC. 
 WT and MUC1.Tg mice (n=3/group) were immunized (i.v.) with DC:MUC1p (MUC1p) (1×106 
cells) or unloaded DC (Ctrl). 1d later, isolated DC were pooled and whole cell lysates were 
Western blotted for phospho-STAT3 (A), phospho-p65, (B) or total IκΒα (C). B-Actin is shown 
as a loading control for each blot. Data are representative of 2-3 independent experiments for 
each molecule.  
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Aldh1/2 expression as a new hallmark of splenic DC tolerized by immunization with self-
antigen 
Retinoic acid is a well-characterized dietary metabolite and mediator of tolerance in the gut, and 
is involved in the induction of CD4+ Foxp3+ T cells by CD103+ DC presenting oral and 
commensally derived Ag (76, 116). The last step in RA biosynthesis is the oxidation of 
retinaldehyde to RA by Aldh1/2. Recent data indicate that CD103- DC in the skin and lung also 
express Aldh1/2 (232) and that RA production is not restricted to the intestine. Splenic DC from 
immunized MUC1.Tg  mice expressed both Aldh1 and Aldh1/2 (Figs. 19A-C), while those 
recovered from all other vaccinations did not. There was no difference in the number of CD103+ 
DC after immunization of either WT or MUC1.Tg mice (Fig. 18). This suggests that RA is 
expressed by vaccine-tolerized DC independent of the CD103 marker and may be responsible for 
their observed capacity to preferentially prime Treg (6). 
 
Figure 18 No difference in CD103 expression between DC that produce Raldh1/2 and those that do not. 
 71 
24h after immunization of WT and MUC1.Tg mice (n=3/group) spleens were harvested for 
FACS. Bars represent mean ± SEM and data are representative of 2 independent experiments.   
 
Figure 19 Inducible production of aldehyde dehydrogenase by tolerized DC. 
 WT and MUC1.Tg mice (n=3/group) were immunized (i.v.) with DC:MUC1p (MUC1p) (1×106 
cells) or unloaded DC (Ctrl). 1d later, isolated DC were pooled and qRT-PCR conducted for 
Aldh1  (A). Concurrently, whole cell lysates from recovered DC were Western blotted for 
Aldh1/2 (B) and bands quantified via densitometry (C). Bars represent mean± SEM after 
normalization to respective control vaccinations (A) and are representative of 3 independent 
experiments. 
 
Function of pancreatic enzymes in DC  
 
Expression of “pancreatic” proteases by splenic DC is coordinately regulated such that 
immunization of WT mice with MUC1p results in a 10-40 fold increase in their expression by 
24h, while the same immunization in MUC1.Tg mice results in their profound suppression. We 
found that this expression profile is a predictive biomarker of DC immunogenicity and the 
ensuing T effector or Treg responses (5, 6). However, the actual function of these newly 
discovered enzymes in DC remained unknown.  
We explored the potential function of two of these enzymes, CBP1 and trypsin, as 
representatives of two broad families, metallopeptidases (CBP1) and serine proteases (trypsin). 
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We hypothesized that both might be involved in the processing and/or presentation of MHC II-
restricted peptides derived from MUC1p, since a diverse repertoire of enzymes, including serine, 
aspartyl, and cysteine peptidases, as well as aspraginyl endopeptidase are involved in this 
pathway (89). To test the contribution of trypsin and CBP1 to the ability of DC to prime an 
antigen-specific CD4+ T cell response, we cultured bone marrow derived DC (BMDC) overnight 
in the presence of MUC1p and n-orthophenanthroline, an inhibitor of all metallopeptidases 
including CPB1, or a trypsin-specific inhibitor derived from chicken ovalbumin. Neither 
inhibitor had a direct effect on DC viability as determined by Annexin-V/PI staining (Fig. 20).   
Antigen-loaded DC were then co-cultured for three days with MUC1p-specific TCR.Tg CD4+ T 
cells labeled with CFSE to quantify proliferation. Figs. 21A and 21B show that inhibition of 
metallopeptidases, as measured by inhibition of CPB1, resulted in low CD4+ T cell proliferation 
suggesting lower antigen processing and/or presentation. Inhibition of trypsin did not have any 
effect.   
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Figure 20 Treatment of BMDC with n-orthophenanthroline and trypsin inhibitor from chicken egg white 
does not affect DC viability. 
BMDC were treated overnight with the indicated concentrations of n-orthphenanthroline or 
trypsin inhibitor from chicken egg white. The following day, cells were stained with PI and 
Annexin V to determine the frequency of apoptosis and necrosis. Data are representative of 2 
independent experiments. 
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Figure 21 DC metallopeptidases, including CPB1, are required for optimal proliferation of MUC1p-specific 
CD4+ T cells. 
(A) BMDC were cultured overnight in the presence of 30 μg/mL Poly:ICLC and 30 μg/mL 
MUC1p with or without added protease inhibitors (10μM or 100μM n-orthophenanthroline or 
100μg/mL trypsin inhibitor). The following day, naïve, CFSE labeled, MUC1p-specific CD4+ T 
cells were added to cultures at a 1:5, DC:T cell ratio, and cultured for 3d. Cells were then 
harvested and percent proliferation determined by CFSE dilution. Histograms are representative 
of 2 independent experiments. (B) Quantification of (A). Bars represent mean± SEM with data 
representative of 2 independent experiments.  
 
We found, on the other hand, that suppression of trypsin expression was likely 
responsible for our previously reported observation that DC recovered from MUC1.Tg mice 
migrated shorter distances ex vivo compared to those recovered from immunized WT mice (6). 
In vivo, DC in lymphoid and non-lymphoid tissues must remodel ECM proteins such as collagen, 
elastin and fibronectin by using secreted or membrane bound proteases (233). Because the 
optimal pH of both trypsin and CPB1 activity are within physiologic range (7.5, and 7-9 
respectively) (234, 235), we cultured DC and assayed the supernatants for secreted trypsin and 
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CPB1 by Western blotting. Both proteins were secreted by 40h with the majority of CPB1 being 
the 45kDa pro-enzyme form. There were multiple trypsin bands detected with at least one of 
them corresponding to an active, 23kDa enzyme (Fig. 22A). To determine if there was a 
difference in the ability to degrade ECM between DC recovered from MUC1p-immunized WT 
mice that upregulate these enzymes, and DC from MUC1p-immunized MUC1.Tg mice that do 
not, we plated both DC populations on FITC-Gelatin coated slides and examined them 4h later. 
The regions of the slide devoid of FITC fluorescence correspond to the amount of gelatin 
degraded by the DC. DC from immunized WT mice were able to degrade more FITC-gelatin 
compared to those from immunized MUC1.Tg mice (Figs. 22B and 22C). When we then 
cultured DC on FITC-gelatin in the presence of a specific trypsin inhibitor derived from chicken 
ovalbumin, the ability of DC from immunized WT mice to degrade the matrix was impeded 
(Figs. 22B and 22C). 
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Figure 22 Extracellular trypsin enhances degradation of the extracellular matrix by DC. 
(A) Splenic DC were isolated from naïve, WT mice and cultured for 40h in the presence or 
absence of 30μg/mL Poly:ICLC. Cell-free supernatants were collected and Western blotted for 
the presence of trypsin and CPB1. Data are representative of 3 independent experiments. (B) WT 
and MUC1.Tg mice (n=2/group) were immunized (i.v.) with DC:MUC1p (MUC1p) (1×106 
cells) or unloaded DC (Ctrl). 2d later, splenic DC were isolated, pooled, and plated onto chamber 
slides coated with a FITC-Gelatin matrix in the presence or absence of 100μg/mL of trypsin 
inhibitor. Cells were fixed after 4h and images collected on an epifluorescent microscope and 
quantified with Image J (C). Bars represent mean± SEM. Data are representative of 2 
independent experiments. 
3.4 DISCUSSION 
We previously showed that, immunization with a self antigen almost immediately (i.e. within 
24h) precludes the maturation and immunogenicity of all splenic DC in vivo, and not just the 
relatively few DC that present the antigen (6). This rapid tolerization of all splenic DC in 
immunized MUC1.Tg mice but not in WT mice is likely due to the increased frequency of pre-
existing MUC1p-specific Treg in MUC1.Tg mice (6, 236). Therefore, the earliest effects of 
vaccination occur not just at the stage of T cell priming, which takes several days to realize, but 
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upstream, at the level of Ag-specific interactions between thymically-derived Treg and DC, 
which take only hours to realize. Here, we show that DC tolerized after immunization with a self 
peptide share some characteristics with iDC while concurrently acquiring a novel, transient 
phenotype based on Aldh1/2, trypsin and CPB1 expression. Like iDC, tolerized DC have a less 
inflammatory cytokine/chemokine profile that likely results in impaired DC-mediated 
inflammation and chemotaxis. Specifically, tolerized DC produced less CCL2, suggesting an 
inability to recruit additional CD11c+CCR2+ cells. CCR2+ DC ameliorate progression of 
diabetes in NOD mice expressing CCL2 in the pancreas (228). Conversely, maintenance of 
CCR2 expression by DC serves as another indicator of a cell that is refractory to vaccine-induced 
maturation in vivo. (227, 237). 
Tolerized DC rely on β-catenin, SOCS1/3, NFκΒ, RAR/RXR, HDAC11, zDC and 
STAT3 to induce and sustain various anti-inflammatory programs (60, 100, 119, 121, 182, 238) 
We found that DC isolated from MUC1p-immunized WT mice downregulated SOCS3 as 
expected, but those from immunized MUC1.Tg mice did not increase expression, suggesting that 
SOCS signaling is not involved in our system. Similarly, expression of HDAC11 is inversely 
correlated with the degree of IL-10 transcription.(122). However, tolerized splenic DC did not 
show the expected decrease in HDAC11 and. by extension, did not produce increased levels of 
IL-10 relative to WT (Fig. 23). 
The transcription factor Zbtb46 (zDC), a repressor of DC maturation, was expressed 
approximately 2.5-fold higher in DC from immunized MUC1.Tg mice relative to those from WT 
illustrating another similarity between iDC and vaccine-tolerized DC. Activation of the NFκΒ 
pathway has been shown to be critical for DC maturation (118). Tolerized DC from MUC1.Tg 
mice were deficient in NFκΒ signaling compared to WT, demonstrating a shared transcriptional 
 78 
signature with iDC.  A possible link between zDC and NFkB, other than their shared  
responsiveness to TLR ligands, has not been described. Importantly, the expression of both zDC 
and CCR2, another marker of iDC, decreased when DC were stimulated with a TLR3 agonist 
directly ex vivo, indicating that these cells maintain the potential for maturation/immunogenicity 
when removed from in vivo suppressive signals, and are thus only transiently tolerized. This 
would allow for the host to control a potentially autoimmune response against self Ag while 
preserving the ability to prime a T cell response against foreign Ag, once self Ag was removed  
 
Figure 23 No difference in the amount of IL-10 produced by DC recovered from MUC1p-immunized WT vs. 
MUC1.Tg mice. 
WT and MUC1.Tg mice (n=3/group) were immunized (i.v.) with DC:MUC1p (MUC1p) (1×106 
cells). 1d later isolated splenic DC were cultured with 500ng/mL LPS for 24h with brefeldin A 
added during the last 6h of stimulation. Culture supernatants were then assayed for IL-10 by 
ELISA. Bars represent mean± SEM. Data are representative of 2 independent experiments.  
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DC from immunized MUC1.Tg mice did not produce more IL-10 than those from WT 
(Fig. 23), yet demonstrated increased phosphorylation of STAT3, suggesting that a paracrine 
source of IL-10 was contributing to their tolerized state. We previously showed that both Treg 
and IL-10 actively suppress expression of trypsin and CPB1 in splenic DC, and by extension, 
contribute to tolerizing those DC. Because MUC1.Tg mice have a higher frequency of MUC1p-
specific Treg (28), Treg and paracrine IL-10 may act on DC to induce STAT3 phosphorylation. 
IL-6 also signals through STAT3, however, tolerized DC produce less IL-6 compared to 
immunogenic DC and there is no increase in IL-6 transcript in the spleens of WT or MUC1.Tg 
mice post-immunization (data not shown). The cellular source of this IL-10 remains to be 
identified.  STAT3 can also directly inhibit NFκΒ signaling as well as the production of IL-6 and 
TNFα as observed in DC recovered from immunized MUC1.Tg mice (239). Thus, STAT3 
phosphorylation induced by immunization with self antigen is a novel characteristic of tolerized 
splenic DC not shared by iDC. 
Tolerized DC express Aldh1/2, the enzyme responsible for oxidizing retinaldehyde to 
immunosuppressive RA. CD11c+CD103+ cells from the gut have been shown to use RA in the 
maintenance of tolerance to commensal flora, and RA also plays a role in oral tolerance to food 
Ag (116). RA is also produced by CD11c+CD103- in the lung and dermis (232) demonstrating 
that this molecule is not restricted to the gut, and that CD103 may not be a universal marker of 
RA-producing DC. However, RA production by splenic DC in response to vaccination with a 
self Ag has not, to our knowledge, been demonstrated. This suggests a new mechanism of 
peripheral tolerance in MUC1.Tg mice in which DC inducibly express Aldh1/2 after 
immunization with self Ag, and also represents a characteristic of tolerized DC not shared by 
iDC. 
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 Metallopeptidases including CPB1 are necessary for DC to prime an optimal, antigen-
specific CD4+ T cell response, suggesting that CPB1 may be involved in the generation of MHC 
II-restricted MUC1 peptides. The majority of endolysosomal peptidases involved in generating 
peptides to be loaded onto MHC II are the cathepsins, consisting of cysteine, serine, and aspartyl 
peptidases. It is possible that the metallopeptidase inhibitor we used, n-orthophenanthroline, also 
affected other susceptible enzymes involved in the MHC II pathway.. However, there are 
currently no known metallopeptidases reported to be involved in MHC II processing and 
presentation, and only two carboxypeptidases, suggesting that in this particular pathway, CPB1 
can be implicated as playing a role directly or indirectly in increasing the efficiency of MHC II-
restricted MUC1p presentation (240, 241).  
Our previous data showed that DC recovered from MUC1p-immunized MUC1.Tg mice 
are less motile ex vivo compared to those from WT. We wanted to determine if this was due to a 
defect in the ability of DC to migrate through the ECM. Because ECM degradation is dependent 
on extracellular protease expression, we examined DC and found that they were able to secrete 
trypsin and CPB1, making them candidates for remodeling ECM proteins. Inhibition of trypsin 
decreased the ability of DC recovered from immunized WT mice (immunogenic DC) to degrade 
gelatin, suggesting that it is necessary for remodeling of the ECM. In vivo it is likely that 
suppressed expression of trypsin in tolerized DC from immunized MUC1.Tg mice retards their 
ability to migrate to T cell areas within the spleen, as the majority of DC are initially localized in 
the red pulp and marginal zone (65). We also observed that the 45kDa proenzyme form of CPB1 
was secreted into DC supernatant while an active 23kDa trypsin isoform was secreted. Because 
trypsin activates the CPB1 zymogen (242) it is likely that both enzymes are functional in the 
extracellular space. The active suppression of trypsin and CPB1 expression, and resulting effects 
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on DC gelatinolysis and T cell priming also constitute part of the novel phenotype of splenic DC 
tolerized by immunization. 
Together our data demonstrate that vaccination with self-antigen has an early and global 
tolerizing effect on DC within the draining lymphoid tissue. Once tolerized, these DC possess 
phenotypic hallmarks of iDC as well as novel features precluding their immunogenicity such as 
expression of Aldh1/2, and suppressed expression of trypsin and CPB1 An understanding of 
early events after immunization will ultimately allow for better rational design of vaccines.  
3.5 MATERIALS AND METHODS 
Mice 
C57BL/6 (WT) mice were purchased from The Jackson Laboratory. MUC1.Tg mice were 
originally purchased from Dr. Sandra Gendler (Mayo Clinic) (219) and subsequently bred at the 
University of Pittsburgh. All colonies were housed under specific pathogen free-conditions. 
Experiments were approved by the Institutional Animal Care and Use Committee at the 
University of Pittsburgh.  
 
Peptides 
A 100-mer MUC1p represents five repeats of the 20-aa sequence 
HGVTSAPDTRPAPGSTAPPA from the MUC1 VNTR region. It was synthesized as described 
previously by the University of Pittsburgh Genomics and Proteomics Core Laboratories (4). 
 
 
 82 
DC Culture and Vaccines 
Bone marrow–derived DC (BMDC) were generated according to a previously reported protocol 
(5). Briefly, female C57BL/6 mice (Jackson) were sacrificed and their femurs and tibiae 
harvested. Marrow was flushed with RPMI-1640 and cells were passed through a 70-mM 
strainer and pelleted before RBC lysis using ACK buffer. Cells were resuspended in AIM-V 
(Life Technologies), counted, and plated at 1.25* 106/mL in AIM-V containing 20 ng/ml GM-
CSF (Miltenyi Biotec). On days 3 and 5, half of the media was replaced with fresh AIM-V and 
GM-CSF. On day 6 of culture, DC were harvested with 2 mM EDTA, counted, and (when 
indicated) loaded with 30 μg/ml MUC1 100-mer and matured with 30 μg/ml polyinosinic-
polycytidylic acid and poly-L-lysine (Poly-ICLC; Hiltonol), a generous gift from Oncovir, 
overnight. On day 7, cells were harvested as above. For immunizations, day 7 DC were washed 
and resuspended in sterile PBS. Mice were immunized i.v. via the lateral tail vein with 1*106 
DC.  
 
DC Protease Inhibition 
BMDC were cultured overnight in the presence of 10μM or 100μM N-orthophenanthroline 
(Sigma) or 100μg/mL of trypsin inhibitor from chicken ovalbumin (Sigma), and 30μg/mL 
MUC1p 100mer, and 10ng/mL GM-CSF (Miltenyi). The following day, MUC1p-specific 
TCR.Tg CD4+ T cells (VFT) labeled with 5μM CFSE (Invitrogen) were added to culture at a 
5:1, CD4:DC ratio. After 3d of coculture, cells were harvested and T cell proliferation 
determined by CFSE dilution on an LSR II cytometer (BD).  
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Quantitative RT-PCR 
RNA was extracted from bead-isolated CD11c+ splenic DC (Miltenyi) using an RNeasy Mini kit 
(Qiagen) according to the manufacturer’s protocol. Reverse transcription was performed using 
Oligo(dT) primes and SuperScript III reverse transcriptase (Invitrogen). cDNA was amplified 
using the following primers: CCR2 (forward: 5’-CTGCAAAGACCAGAAGAGGGC-3’, 
reverse: 5’-CCACCACCCAAGTGACTACA-3’), SOCS3 (forward: 5’-
CCAGCCTGCGCCTCAAGACC-3’, reverse: 5’-GCGTGCTTCGGGGGTCACTC-3’), Aldh1 
(forward: 5’-CCATGCCGGGCGAGGTGAAG-3’, reverse: 5’-
TCCGGGTGGAAAGCCAGCCT-3’), and zDC (forward: 5’-
AGAGAGCACATGAAGCGACA-3’, reverse: 5’-CTGGCTGCAGACATGAACAC-3’). 
Quantitative PCR was conducted using a QuantiTect SYBR Green Kit (Qiagen). Reactions were 
run on a StepOne Plus cycler (Applied Biosystems) with data generated using ΔCT methodology 
(221).  
 
Western Blotting 
Cells were lysed in RIPA buffer and proteins run on 10% Tris-HCL Mini-PROTEAN TGX gels 
(Bio-Rad) followed by transfer onto a polyvinylidene difluoride membrane. Membranes were 
blocked in 5% milk followed by overnight incubation at 4° with one of the following Abs: Rb X-
trypsin (M-60), Rb X-CPB1 (M-134), Ms X-Aldh1/2 (H-8), Rb X-IκΒ-α (C-21) or Rb X-p-
STAT3 (Ser 727) (Santa Cruz), and Rb X-p-p65 (93H1) (Cell Signaling). 
 
Cytokine Array 
DC were MACS (Miltenyi) isolated from spleens 24h post-MUC1p immunization of WT and 
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MUC1.Tg mice. DC were then cultured overnight in the presence of 500ng/mL LPS (Sigma) and 
GolgiPlug (BD). The following day, cells were lysed and total DC protein queried for 
cytokine/chemokine expression using a Proteome Profiler Array (R&D Systems). Densitometry 
was conducted on blots using Image J (NIH).  
 
Gelatin Degradation Assay 
DC were MACS isolated (Miltenyi) from spleens 24h post-immunization of WT and MUC1.Tg 
mice. Cells (1×105) were immediately plated into 8-well chamber slides coated with FITC-
Gelatin using the QCM Gelatin Invadopodia Kit (Millipore). Images were collected on an 
Olympus Provis fluorescent microscope with a 40X objective. Areas of FITC-Gelatin 
degradation were quantified at 4h and 24h using binary thresholding in Image (NIH). Where 
indicated, DC were cultured for indicated timepoints in the presence of 10μM N-
orthophenanthroline and/or 100ug/mL trypsin inhibitor from chicken ovalbumin (Sigma). 
 
CCL2 Chemotaxis Assay 
WT and MUC1.Tg mice were immunized with DC:MUC1p and splenic DC MACS isolated 
(Miltenyi) 24h later. DC were labeled with 5μM CFSE (Invitrogen) and 1.8*104 DC were plated 
into one chamber of a μ-chemotaxis slide (Ibidi) while the opposite chamber was filled with 
media containing 2μg/mL of recombinant CCL2 (Peprotech). After 1h at 37° during which a 
stable linear gradient of CCL2 was established, cells were imaged at 1 frame/5min on a Nikon 
live cell system for 6h.  Data was quantified and plotted using WinTaxis (Wimasis) tracking only 
DC that showed directional chemotaxis towards the CCL2 gradient.  
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4.0  TRANSCRIPTIONAL PROFILE OF WT AND MUC1.TG MICE IMMUNIZED 
WITH TN.MUC1, A HYPOGLYCOSYLATED ANTIGEN RESTRICTED TO 
MALIGNANT AND INFLAMED EPITHELIA 
4.1 ABSTRACT 
While MUC1.Tg mice do not mount a robust immune response after vaccination with MUC1p 
due to peripheral tolerance, the addition of disease-specific sugar moieties render it significantly 
more immunogenic. This is a result of cryptic peptide epitopes that are revealed to T cells by 
disease-restricted glycosylation, and the ability of those glycoepitopes to be processed and 
presented by DC.  We were interested in determining the early (24h) events in the spleen that 
contribute to the immunogenicity of MUC1.Tn-based vaccines in both WT and MUC1.Tg mice. 
Accordingly, we immunized both strains with DC loaded with MUC1.Tn (DC:Tn100mer) and 
analyzed differentially expressed transcripts in total splenic RNA by microarray. We found that 
in spite of the equivalent immunogenicity of DC:Tn100mer in both WT and MUC1.Tg mice, 
there were signatures of two different types of immune response to the same vaccine. Immunized 
WT mice induced transcripts associated with DC, DC recruitment, and DC cross-presentation, 
while MUC1.Tg mice expressed a plethora of genes associated with the Type I IFN response. 
These results demonstrate that seemingly divergent early responses to vaccine-delivered antigen 
can ultimately result in the same degree of immunogenicity days and weeks later.  
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4.2 INTRODUCTION 
Malignant transformation and inflammation of ductal and glandular epithelial cells results in an 
altered profile of MUC1 expression that includes loss of polarity, overexpression, and 
hypoglycosylation (164, 243, 244). These biochemical differences between “normal” and 
“tumor” MUC1 make it an attractive target for both immunoprevention and immunotherapeutic 
vaccine strategies due to better accessibility to the immune system, and the disease-restricted 
revelation of cryptic peptide epitopes. In mouse models, TCR.Tg CD4+ T cells that recognize an 
epitope derived from a hypoglycosylated MUC1 peptide (i.e. RFT cells recognizing the 
TnMUC1 peptide) proliferate equivalently after vaccination in both WT and MUC1.Tg mice, 
demonstrating a lack of peripheral tolerance against this antigen (5, 176). Conversely, CD4+ T 
cells that recognize unglycosylated MUC1 (i.e. VFT cells recognizing the MUC1p peptide) 
proliferate less after immunization in MUC1.Tg mice compared to WT due to peripheral 
tolerance against MUC1p as a self-antigen (4, 5). Importantly, these tumor-associated epitopes 
are recognized by cytotoxic T lymphocytes (CTL) in patients with multiple malignancies, 
including breast and pancreatic cancer (245, 246). Therapeutic immunization of prostate cancer 
patients with a polyvalent vaccine consisting, in part, of a TnMUC1 32mer stimulated a high 
titer, specific IgG response, and a current Phase I/II trial examining the efficacy of a DC vaccine 
loaded with the Tn antigen in prostate cancer is currently underway (247)  (Trial NCT00852007, 
clinicaltrials.gov).  
Hypoglycosylation of MUC1 does not result in decoration of its peptide backbone with a 
random assortment of sugar moieties. Rather, short, conserved glycoantigens such as the Tf, Tn, 
and sialyl-Tn antigens are generated due to premature carbohydrate chain terminations by 
glycosyltransferases (159, 162). The Tn antigen has been particularly well characterized and 
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consists of an O-linked N-acetylgalactosamine (GalNAcα-O-S/T) added in the Golgi by a 
polypeptide-N-acetylgalactosaminyltransferase (248). This glycoepitope is not removed during 
antigen processing by DC, and is recognized by cognate, glycopeptide-specific CD4+ T cells 
(224).  
Because of the universal immunogenicity of the MUC1.Tn antigen in WT and MUC1.Tg 
mice, we were interested in understanding early, global events in the spleen after i.v. 
immunization. Accordingly, mice were immunized with DC:Tn100mer and total splenic RNA 
was extracted at 24h and 72h post-immunization followed by whole transcriptome analysis. We 
found overexpression of CXCR4, CCL21, CD207, HSP105, and CD14 in immunized WT mice 
and overexpression of CTLA-4 and IRF7 in immunized MUC1.Tg mice. Data from the 24h 
timepoint are presented here as there were no changes in the relative expression of these 
transcripts, nor any new transcripts expressed at 72h. 
4.3 RESULTS 
Expression differences between WT (n=3) and MUC1.Tg (n=3) mice immunized with 
DC:Tn100mer were determined by microarray analysis of pooled, total splenic RNA at 24h post-
immunization. Data were analyzed using the Gene Set Enrichment Analysis program (GSEA). 
GSEA determines changes in the expression of single genes as well as allowing for the 
comparison of cohorts of genes that belong to related signaling pathways (249). Examination of 
the 50 most overexpressed and underexpressed transcripts in immunized MUC1.Tg mice relative 
to immunized WT revealed differential expression of multiple immune and non-immune related 
genes (Fig. 24) 
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The most statistically significant, differentially expressed, immune-related genes were 
HSP105, CD14, CD207, CXCR4, and CCL21A and were preferentially induced in WT mice, 
while IRF7 was induced in MUC1.Tg mice. Both sets of genes can mediate immunogenic 
functions via different mechanisms, as might be expected for a vaccine that induces strong 
immunity in both mouse strains. HSP105 is a positive regulator of NKT cell activation as well as 
MHC I biosynthesis (250). Interestingly, CD207 (Langerin), considered a marker of skin-
resident Langerhans cells, is also expressed on marginal zone, CD8αα+ DC (251). CD14 is a co-
receptor, along with MD2 and TLR4, for LPS and is expressed by myeloid cells including DC, 
while CCL21 is a potent chemoattractant for naïve T cell and iDC homing to and within 
secondary lymphoid tissue. CXCR4 has well-characterized functions as an HIV-1 co-receptor on 
T cells, however it is has also been implicated, along with its ligand, CXCL12 in DC survival 
and chemotaxis (252). These molecules may constitute the early phase of a DC-centric immune 
response to Tn100mer in WT mice. Conversely, IRF-7, along with IRF-3, are master regulators 
of the Type I interferon response in virally infected cells as well as pDC suggesting a possible 
early, innate-type inflammatory response underlying Tn100mer immunogenicity in MUC1.Tg 
mice dependent on Type I IFN signaling (253).  
While not all statistically significant, examination of DC:Tn100mer-induced 
transcriptional changes by gene sets rather than individual genes provides some insight into how 
this vaccine affects several important pathways. Figure 25 shows heat maps comprised of genes 
associated with the CCR5 and STAT3 pathways, along with genes involved in the general 
inflammatory response. In the inflammatory cluster, the only consistent changes amongst the 
technical replicates were the overexpression in MUC1.Tg spleens of Cathepsins C and S. Both 
enzymes are involved in antigen processing and presentation in APC, with cathepsin S cleaving  
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Figure 24  Differentially expressed genes in WT and MUC1.Tg mice immunized with DC:Tn100mer. 
WT and MUC1.Tg mice (n=3/group) were immunized i.v. with BMDC loaded with 34ug/mL of 
Tn:100mer. 24h later, total splenic RNA was pooled and whole transcriptome analysis 
conducted. Technical triplicates were run on arrays (Samples WT Tn 1-3 and Tg Tn 1-3). The 
heat map represents fold changes in MUC1.Tg mice relative to WT. Red and pink signify 
overexpression while blue and light blue represent underexpression. Data were analyzed using 
GSEA. 
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MHC II invariant chain into CLIP before H2-M catalyzed loading of peptide (89). In the STAT3 
cluster IFIT3 was upregulated in MUC1.Tg mice. This protein plays a downstream role in the 
Type I interferon response, fitting in with the induction of IRF7 in the same animals. In the 
CCR5 cluster there was induced expression in WT mice of CXCL12, (SDF-1), the ligand for 
CXCR4.  
 
Figure 25 Changes in CCR5, STAT3, and inflammatory pathway genes in WT and MUC1.Tg mice 24h post-
vaccination with DC:Tn100mer.  
Single transcript fold changes were grouped into gene clusters using curated gene sets from GSEA. 
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Figure 26 Changes in Type I IFN, TGF-β, and Foxp3 pathway genes in WT and MUC1.Tg mice 24h post-
vaccination with DC:Tn100mer. 
Single transcript fold changes were grouped into gene clusters using curated gene sets from 
GSEA. 
 
Examination of the Type I IFN pathway cluster showed an overall enhanced induction of 
Type I IFN signaling in immunized MUC1.Tg mice relative to WT as would be expected to 
coincide with the relative overexpression of IRF7 and IFIT3. Interestingly, there was decreased 
SOCS1/3 transcript in WT mice. The suppressor of cytokine signaling proteins (SOCS) act to 
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preclude production of pro-inflammatory cytokines, particularly in DC. In the Foxp3 cluster, 
there is a trend towards induction of CTLA-4 and IL-2Ra in immunized MUC1.Tg mice. These 
mice have more MUC1-specific, thymically-derived Treg compared to WT, and these transcripts 
may reflects an early, direct, or MUC1p-cross reactive regulatory response to Tn100mer. There 
were no consistent changes in genes associated with the TGF-β cluster.  
4.4 DISCUSSION 
The addition of tumor-specific carbohydrates to the MUC1 100mer allows for recognition by a T 
cell repertoire that is not subject to the same mechanisms of peripheral tolerance that those 
specific for unglycosylated peptide are. As a result, the Tn100mer is equivalently immunogenic 
in both WT and MUC1.Tg mice (5, 211). Microarray analysis of early, global changes in gene 
expression in the spleen suggests that WT and MUC1.Tg mice initially engage different 
programs, that ultimately result in a similar degree of immunogenicity (as measured by 
equivalent RFT proliferation) in both mouse strains. Vaccination of WT mice with 
DC:Tn100mer induces expression of a group of DC-related genes, particularly those that may be 
involved in initiating cross-priming of a TnMUC1-specific CD8+ T cell response. CD207 
expression in the spleen coincides with CD8αα+ DC, a population considered to have enhanced 
cross-priming capability (68, 251, 254). In combination with higher expression of HSP105, 
which acts as a positive regulator of MHC I biogenesis (250), enhanced cross-presentation of 
Tn100mer is a possibility. Immunized WT mice also show additional hallmarks of DC 
involvement and immunogenicity within the first 24h. Induction of CD14, whose expression is 
restricted mainly to myeloid cells, particularly DC and macrophages, suggests enhanced 
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recruitment or retention of those populations after immunization. CCL21 expression, likely by 
CD45- stromal cells, is a potent chemotactic molecule for naïve T cells and DC and may underlie 
the relative surfeit of DC-related transcripts in WT spleens, as well as acting to recruit circulating 
T cells. Interestingly, expression of SOCS1 and SOCS3 were not expressed in WT mice to the 
degree they were in MUC1.Tg. SOCS proteins are critical inhibitors of proinflammatory 
cytokine production by DC (238), again supporting an immunogenic role for DC in initiating the 
immune response against Tn100mer. Finally, immunized WT mice had enhanced expression of 
CXCR4. CXCR4 has been shown to decrease the expression of the anti-apoptotic protein Bcl-2 
in DC thus enhancing DC survival (252). If the CXCR4 expression is confined to DC, this would 
further support an early, and sustained immunogenic response to MUC1.Tn in WT mice that is 
likely DC-mediated. 
In contrast to the transcriptional program initiated in WT mice, the response to 
immunization with Tn100mer in MUC1.Tg mice appears to rely more on the initiation of Type I 
IFN signaling. The higher relative expression of IRF7, IFITM3 and numerous other genes up and 
downstream of IFNα/β signaling supports an early, biased response that may be mediated by 
pDC (Fig. 26). Somewhat counter-intuitively, there is preferential induction, albeit not within the 
cohort of genes with the highest fold changes, of the suppressive Treg-associated genes CTLA-4 
and IL-2Rα. Because Tn100mer induces immunity in MUC1.Tg mice, these suppressive 
transcripts represent either an early, and ultimately overcome, regulatory response, or the 
presence of Tn100mer-specific Treg that are present in the MUC1.Tg spleen, but not WT. The 
medullary thymic epithelial cells of both humans and MUC1.Tg mice express glycosylated and 
unglycosylated MUC1, while thymi from WT do not (28). Therefore, the enrichment in CTLA-4 
and IL-2R are most likely derived from thymic Treg that are resident in the spleen. Interestingly, 
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there was no differential expression of either trypsin or CPB1 in splenic RNA from WT or 
MUC1.Tg mice. We would hypothesize that the immunogenicity of MUC1.Tn would result in 
induction of these enzymes in DC from both mouse strains, therefore precluding the detection of 
differences in expression that were determined using GSEA.  
This analysis represents the first step towards understanding the mechanisms behind the 
immunity induced by an effective vaccine in WT and MUC1.Tg mice. While it will be important 
to determine in which splenic compartment each gene is changing expression in, it is tempting to 
speculate that the early role endogenous DC play in mediating tolerance after immunization with 
a self-antigen may also be true after immunization with an “abnormal-self” or “foreign” antigen. 
A comprehensive understanding of the early response to effective and ineffective MUC1 
vaccines is important to improvements in future iterations.  
4.5 MATERIALS AND METHODS 
Mice 
C57BL/6 (WT) were purchased from the Jackson Laboratory. MUC1.Tg mice were purchased 
from Dr. Sandra Gendler (Mayo Clinic) (219) and bred in the University of Pittsburgh animal 
facility. All colonies were bred and maintained at the University of Pittsburgh under specific 
pathogen free conditions. Experiments were approved by the Institutional Animal Care and Use 
Committee of the University of Pittsburgh.  
 
Peptides 
A 100mer MUC1 peptide (MUC1p) represents 5 repeats of the 20- amino-acid sequence 
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HGVTSAPDTRPAPGSTAPPA from the extracellular, MUC1 VNTR region. It was synthesized 
as described previously (4) by the University of Pittsburgh Genomics and Proteomics Core 
Laboratories. The Tn100mer peptide was synthesized by enzymatic addition of GalNAc moieties 
to the 100mer via recombinant human UDP-GalNAc:polypep- tide N-acetyl-
galactosaminyltransferase rGalNAc-T1 (5) 
DC culture and vaccines 
BMDC were generated according to established protocol (5). Briefly, female C57BL/6 mice 
(Jackson) were sacrificed and their femurs and tibiae removed. Marrow was flushed with RPMI 
(2% FCS, 1% Penn-Strep and 2-ME). Cells were passed through a 70μM strainer and pelleted 
before RBC lysis using ACK buffer. Cells were resuspended in AIM-V (Gibco), counted and 
plated at 1.5-2×106/mL in AIM-V containing 20ng/mL GM-CSF (Miltenyi). On d3 and d5 half 
the media was replaced with fresh AIM-V and GM-CSF. On d6 of culture, DC were harvested 
with 2mM EDTA, counted and loaded with 34μg/mL TnMUC1 100mer and matured with 
30μg/mL of Poly-ICLC (Hiltonol), a generous gift from Oncovir, overnight. On d7, cells were 
harvested as above. For immunizations, d7 DC were washed and resuspended in sterile PBS. 
Mice were immunized i.v. via the lateral tail vein with 1×106 DC.  
 
Microarray 
Whole spleen from WT and MUC1.Tg mice (n=3/group) was harvested at 24h and 72h post-
immunization with DC loaded with TnMUC1 100mer peptide. RNA extraction was performed 
using Trizol (Invitrogen). RNA from mice within groups was pooled followed by hybridization 
onto Illumina WG6 arrays. Data analysis was conducted using GSEA 
(http://www.broadinstitute.org/gsea) (249).  
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5.0  CONCLUSIONS AND SIGNIFICANCE 
5.1 GLOBAL CONCLUSIONS 
In this study we show that the relative expression of a group of “pancreatic” enzymes by splenic 
DC after vaccination is an early marker of the ensuing immune response, distinguishing future 
effective immunity from tolerance. Intravenous vaccination of MUC1.Tg mice with MUC1p, or 
RIP.OVA mice with OVA (as representative self-antigens) results in the suppressed expression 
of trypsin and CPB1 by splenic DC, while vaccination of WT mice with MUC1p or OVA (as 
representative foreign antigens) results in their upregulation. Therefore, expression of trypsin and 
CPB1, after immunization with a foreign peptide, is induced in all DC in the draining lymphoid 
organ and suppressed after immunization with self-peptide. We show that both IL-10 and Treg 
actively prevent expression of these enzymes, as pre-immunization depletion of either restores 
trypsin and CPB1 to WT levels. Importantly, DC with suppressed enzymes post-vaccination are 
phenotypically and functionally tolerized, as determined by reduced expression of CD40, CD86 
and MHC II, a less inflammatory cytokine/chemokine profile, and ability to prime naïve CD4+ T 
cells into Foxp3+ Treg versus IFNγ+ cells ex vivo (Fig. 27). We suggest that our data provides in 
vivo support for a two-step model of infectious tolerance: the transfer of tolerance from one 
population of cells to another (205). The first transfer of tolerance occurs when a MUC1p-
specific Treg recognizes a DC presenting MUC1p and signals it to suppress expression of 
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pancreatic enzymes (i.e. trypsin and CPB1). The higher frequency of MUC1p-specific Treg in 
MUC1.Tg mice compared to WT means that the DC from immunized MUC1.Tg mice are 
induced to suppress enzyme expression while those from WT are not. This enzymatic profile is a 
marker of a DC that has become tolerized, and these DC subsequently fail to recruit and prime 
cognate CD4+ effector T cells, resulting in a second transfer of antigen-specific tolerance to naïve 
CD4+ T cells (Fig. 27). Vaccine-mediated effects on DC occur rapidly, but with each transfer of 
tolerance characterized by different kinetics. In MUC1.Tg mice, Treg suppress DC trypsin and 
CPB1 within hours, while the downstream effects of tolerized DC on T cell proliferation and 
phenotype occur within days. Combined with a decrease in motility and corresponding ability to 
degrade the ECM, these tolerized DC constitute an additional layer of peripheral tolerance 
against the generation of T cell responses directed against MUC1 as previously reported (4, 5, 
173, 175, 191, 211).  
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Figure 27 Propagation of tolerance to the self-antigen MUC1p in vivo. 
Immunization of MUC1.Tg mice with MUC1p results in the rapid tolerization of Ag-presenting 
DC by cognate thymic Treg. These DC are prevented from upregulating expression of trypsin, 
CPB1 and other “pancreatic” enzymes. This profile of suppressed enzyme expression is a marker 
of a DC that is tolerized as determined by low costimulatory molecule expression, decreased 
motility, and decreased chemotactic and inflammatory cytokine/chemokine production. These 
DC subsequently prime Treg rather than effector CD4+ T cells. The role of CCL2 in recruiting 
additional DC to the spleen as well as the role for MIP-1b, RANTES, and IL-16 in precluding 
productive contacts between DC and CD4+ T cells is currently unknown.  
 
Some of the mechanisms underlying DC tolerization after vaccination with MUC1p are 
shared with iDC. There are, however, additional novel mechanisms we identified in DC that 
contribute to, and perpetuate tolerance against self-antigen. Like iDC, tolerized DC have 
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decreased activation of the NFκβ pathway, and sustained expression of zDC and CCR2 
compared to the immunogenic DC from MUC1p-immunized WT mice. Unlike iDC however, 
these tolerized cells have enhanced phospho-STAT3 expression, mediated upstream by increased 
sensitivity to IL-10, as well as inducible expression of Aldh1/2, and likely RA (Fig. 28). This 
tolerized state is transient as DC from MUC1p-immunized MUC1.Tg mice are not refractory to 
maturation with TLR ligands ex vivo. This demonstrates that the suppressive factors required in 
vivo to tolerize DC in a MUC1p-specific fashion (e.g. Treg and IL-10) do not do so terminally. 
After the threat of self-antigen passes, these splenic DC are capable of maturing and initiating 
immunity to appropriate foreign antigens. Therefore, DC tolerized after immunization with self-
antigen do not simply fail to mature, but rather share characteristics of iDC in addition acquiring 
more active mechanisms to transiently prevent induction of immunity to self.  
In addition to showing that DC express the enzymes trypsin and CPB1 amongst others 
(Table I), we present data demonstrating their involvement in DC immunogenicity. Accordingly, 
an additional, novel hallmark of tolerized DC that distinguish them from iDC is the functional 
consequence of actively suppressed trypsin and CPB1 expression. Trypsin, secreted by DC, is 
required for optimal degradation of the ECM. As a result, tolerized DC with suppressed trypsin 
expression may not be able to traffic efficiently to T cell areas within secondary lymphoid tissue 
as a variety of enzymes, including matrix metalloproteinases, are required for DC migration 
within tissues (255, 256). Metallopeptidases, including CPB1, are required for optimal 
presentation of MUC1p to cognate CD4+ T cells. This constitutes another mechanism by which 
tolerized DC can also be described as “tolerogenic”, in that the ineffective processing and 
presentation of MUC1p due to suppressed CPB1 expression precludes priming of an optimal T 
cell response. It is possible that the priming of naïve CD4+ T cells by tolerized DC into Treg is 
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mediated in part by the suboptimal presentation of MUC1p:MHC II complexes, as lower pMHC 
density on DC can favor Treg rather than effector T cell development (80, 257). 
 
Figure 28 Signaling pathways underlying tolerized DC. 
DC tolerized after immunization with self-antigen share some of the signaling pathways that 
underlie iDC such as sustained expression of zDC and suboptimal NFkB activation. However, 
these DC also show increased STAT3 phosphorylation and inducible expression of Aldh1/2 
revealing the simultaneous acquisition of active mechanisms of tolerance. The cellular source of 
IL-10 and the contribution of the combination of RA and TGF-β to iTreg generation has not been 
determined. 
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5.2 SIGNIFICANCE 
Our results identify the relative expression of “pancreatic” enzymes in splenic DC as a very early 
biomarker predictive of the ensuing immune response to a given vaccine. Trypsin and CPB1 
expression measured as early as 24h post-vaccination is highly correlated with the relative 
immunogenicity of the DC in which it occurs (6). Furthermore, we show that the relative 
immunogenicity of splenic DC after i.v. immunization determines the quality of the CD4+ T cell 
response against MUC1 (5). Current correlates of vaccine protection often rely on measuring 
antibody titers or T cell responses that take days or weeks to develop, so the ability to predict 
vaccine efficacy within hours represents a potentially useful advance (258). Similarly, the assays 
used to quantify the response to vaccination, with the exception of flow cytometry, (e.g. ELISA, 
ELISPOT, ex vivo cytotoxicity) are multiday procedures. While our results represent an 
important proof of concept, challenges remain before DC-based biomarkers are translated. 
Firstly, current correlates of vaccine protection are largely based on Ig levels and T cell 
responses derived from sera and peripheral blood mononuclear cells (PBMC). While the degree 
to which a tissue-based immune response is mirrored in the peripheral circulation is 
questionable, the convenience of monitoring serial blood draws from a patient to track vaccine 
response is not to be overlooked. However, in both mice and humans DC only constitute around 
1% and .5% of PBMC respectively, with the majority localized in lymphoid and parenchymal 
tissues (259, 260). This presents potential obstacles in isolating and purifying enough DC from 
the blood to quantify enzyme expression (limited mostly by the requirement for enough RNA to 
perform qPCR), as well as the possibility that peripheral DC will not show changes in trypsin 
and CPB1. An alternative would be to examine these markers in monocyte-derived DC from 
PBMC as established protocols exist to differentiate peripheral mononuclear cells (261), and 
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these cells express CPB1 and elastase (6). However, changes in expression after vaccination 
have not yet been examined in these cells.  
Secondly, we examined endogenous DC in the draining lymphoid tissue, the spleen, after 
intravenous immunization. Most cancer vaccines, with the exception of some DC-based 
vaccines, are administered either intramuscularly, intradermally, or subcutaneously (262). As a 
result, collecting DC from the relevant draining LN would require biopsy followed by isolation. 
While this is technically feasible it represents a more invasive procedure, and the benefit to risk 
ratio would have to be acceptable for it to be a viable option.  
Our results also contribute to a previously underappreciated role for endogenous DC in 
influencing the direction of the ensuing immune response to vaccination. It is generally thought 
that DC-based vaccines act by directly presenting antigen to cognate T cells, with the subsequent 
response contingent on both the immunizing antigen as well as the phenotype of the vaccine DC. 
Recently it has been demonstrated that the viability and MHC II expression of the DC used for 
vaccination are dispensable, and it is DC-derived antigen processed by endogenous DC that 
directly primes the T cell response (263). Our data show that post-vaccination changes in the 
phenotype of the splenic DC compartment are global, suggesting a mechanism by which DC 
tolerance initiated by Treg is transmitted to the entire DC population, tissue-wide. This data 
underscores the importance of vaccine antigen choice by highlighting a system in which vaccine 
signals are quickly and efficiently dispersed and amplified.  
We also identify inducible expression of Aldh1/2 in CD103- splenic DC in response to 
immunization with self-antigen. While the immunosuppressive metabolite of Aldh1/2 activity, 
RA, is a well-described mediator of tolerance to oral, respiratory and commensal antigens in the 
gut and lungs, its function has not been well characterized either in the spleen, nor in response to 
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vaccine-delivered antigens (76, 116). Similarly, the phenotype assumed by tolerized DC is a 
unique mosaic of both canonical features of DC-mediated tolerance (e.g. low costimulatory 
molecule expression and anti-inflammatory cytokine production), combined with the novel, 
immunomodulatory functions of trypsin and CPB1 that we describe. Our identification of trypsin 
and CPB1 expression and function in splenic DC adds to the growing list of potential molecules 
and pathways that can be targeted to modulate DC function, before and after vaccination. 
5.3 REMAINING QUESTIONS 
 
Like all new information, our results open as many questions as they answer. Our data showing 
changes in endogenous DC phenotype were all measured using total, splenic DC. Therefore, 
either a small subset of DC dramatically changes phenotype (e.g., enzyme expression, cytokine 
production etc.) such that the observed differences are apparent in the population as a whole, or 
the majority of cells within that population undergo more biologically feasible changes in 
phenotype. We propose that the latter is the more likely scenario and that there are at least two 
major mechanisms by which the introduction of relatively few antigen-bearing, vaccine DC 
might propagate either a tolerogenic or immunogenic signal to all other DC in the draining 
lymphoid tissue. First, antigen derived from vaccine DC could be distributed to all other 
endogenous DC in the tissue. This could occur through the shedding and subsequent 
internalization of antigen-containing exosomes or via the transfer of antigen through physical, 
tubular connections between DC termed tunneling nanotubules (204, 264). Second, cognate 
Treg:DC interactions could be relatively few, with the resulting signaling mediators (e.g., 
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calcium flux) being transmitted to all tissue DC rather than antigen. As discussed in Appendix C, 
a variety of microscopic approaches need to be utilized to address the precise mechanism by 
which vaccine DC integrate into the resident DC network. 
We show that Aldh1/2 is made by tolerized DC. However, a direct role for RA, in 
conjunction with TGF-β, as being involved in the priming of Foxp3+ inducible Treg by tolerized 
DC ex vivo remains to be determined. Similarly, the relative contributions of low costimulation 
and fewer MUC1p:MHC II complexes (due to suppressed CPB1 expression) to the ability of 
tolerized DC to prime Treg is unknown. That is, would RA, low costimulation, or suppressed 
CPB1 expression alone maintain the tolerogenicity of these DC, or do all three mechanisms act 
in concert to produce the observed function.  
Our observations demonstrating impaired ex vivo motility of tolerized DC as well as their 
relative inefficiency in degrading ECM raise important questions regarding how effectively these 
DC can interact with cognate effector T cells in vivo. During homeostasis, the majority of DC are 
localized in the splenic marginal zone, or scattered throughout the white pulp, however, they 
must respond to a CLL19/CCL21 gradient to migrate to T cell areas during their maturation (65). 
While there are equivalent numbers of VFT CD4+ T cells in the spleen after adoptive transfer, it 
remains to be determined whether there are an equivalent number of productive DC:VFT 
interactions in immunized WT and MUC1.Tg mice. The decrease in tolerized DC motility and 
gelatinolysis in concert with their decreased production of T cell chemokines may act as an 
additional safeguard against autoimmunity by precluding the ability of DC to physically traffic to 
T cell areas in the spleen.  
Finally, we show that the endogenous DC compartment is only transiently tolerized after 
exposure to self-antigen. DC stimulated ex vivo can be induced to mature with TLR ligands, and 
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levels of trypsin and CPB1 return to baseline several days after immunization. The signaling 
networks responsible for a return to the steady-state, be they decreased IL-10, the egress or 
apoptosis of cognate Treg, or others, remain to be determined. Additionally, at the biochemical 
level, an understanding of what molecules control transcription of trypsin and CPB1 would be of 
utility to identify potential overlaps with the IL-10, NFκβ, STAT3 and zDC pathways. Similarly, 
identifying the enzymatic cascade upstream of bioactive trypsin and CPB1 formation remains to 
be determined. In the duodenum, secretion of enterokinase cleaves trypsinogen into active 
trypsin which then acts both in an autocatalytic loop, as well as activating pro-CPB1 to CPB1 
(265). While our array data did not show any differential expression in enterokinase between 
immunized MUC1.Tg and WT mice, its relevance in potentially activating DC-expressed trypsin 
would still be useful to examine given the limits of microarray sensitivity. A more nuanced 
understanding of the regulatory networks controlling DC tolerance versus immunity will allow 
for interventional modulation so as to drive the immune system towards the desired outcome.  
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APPENDIX A 
SUBCELLULAR LOCALIZATION OF TRYPSIN AND CPB1 
Our data suggests a role for CPB1, and likely additional metallopeptidases, in mediating optimal 
CD4+ T cell priming by DC. When CPB1 activity was inhibited using the broad metallopeptidase 
inhibitor n-orthophenanthroline, DC were unable to induce efficient proliferation of cognate, 
MUC1p-specific CD4+ T cells compared to control. The generation of MHC II-restricted 
peptides depends on processing by various proteolytic enzymes such as the cathepsins in 
progressively more acidic endolysosomal compartments. Ultimately, peptides derived from the 
original protein are loaded onto empty MHC II molecules by H2-M before transport via 
endolysosomal tubules to the plasma membrane (83, 93, 266, 267). Accordingly, we were 
interested in determining the sub-cellular localization of CPB1 with the hypothesis being that it 
would be expressed in compartments associated with Class II processing and presentation. 
Additionally, since DC maturation is accompanied by enhanced lysosomal acidification and 
peptide processing (62), we wanted to assess any differences in CPB1 quantity and/or 
distribution after a variety of maturational stimuli.  To this end, bone marrow-derived DC 
(BMDC) were permeabilized and stained for trypsin, CPB1 and MHC II after no treatment, or 
overnight culture with LPS, Poly:ICLC, or X-CD40. Cells were then fixed and imaged with 
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confocal microscopy. As shown in Figure 29, both enzymes are predominantly cytosolic in the 
steady state with a large degree of overlap with internal MHC II, perhaps in MHC II 
compartments (MIIC) (268).  
 
Figure 29 Trypsin and CPB1 move towards the periphery of BMDC after maturation. 
 BMDC were left untreated overnight, or stimulated with 1μg/mL LPS, 25μg/mL Poly:ICLC, or 
10μg/mL anti-CD40. Cells were then fixed, permeabilized, and stained with antibodies to trypsin 
or CPB1 (Green) and an antibody to I-Ab (Red) followed by counterstaining with DAPI (Blue). 
Slides were imaged on an upright Olympus Fluoview 1000 at 60X. Data are representative of 2 
independent experiments. 
 
After maturation of DC with LPS, there is a peripheralization of both proteases, with 
CPB1 redistributing away from the nucleus and trypsin moving near the cell membrane. This 
pattern is recapitulated after CD40 and Poly:ICLC induced maturation as well, particularly for 
the membrane distribution of trypsin. Maturation also enhanced co-localization between CPB1 
and intracellular MHC II+ compartments and trypsin and MHC II on or near the membrane. 
These data suggest that CPB1 may be present in late endosomal compartments where peptides 
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are being loaded onto MHC II, while trypsin, which we identified as being secreted by DC and 
important for gelatinolysis, is localized on or near the membrane for remodeling of the ECM.  
LAMP-1 (CD107a) is a marker of acidic, lysosomal and late endosomal compartments 
where chaperoned MHC II molecules are loaded with peptide (269). To further examine which 
endocytic compartments CPB1 may be part of, we performed immunofluorescence as above to 
examine co-localization between the enzymes of interest and LAMP-1+ lysosomes and/or 
endolysosomes.  As shown in Figure 30, there is minimal co-localization between CPB1 and 
LAMP-1+ lysosomes, and no overlap was observed for trypsin (data not shown). This implicates 
CPB1 as playing a role in antigen processing and/or presentation earlier in the MHC II endocytic 
pathway. Its putative localization in MIIC, but not LAMP-1 vesicles suggests that it  catalyzes 
proteolysis of proteins, or plays some other function earlier in the pathway, before maximal 
acidification of the phagolysosome. Because the optimal pH for CPB1 activity is between 7-9 
(235) it would likely not be optimally functional at a typical lysosomal pH of 4.5-6 but would 
operate in the early endosomal pH range of 6.1-6.8 (270).  
 
Figure 30 Minimal Colocalization between CPB1 and LAMP-1+ compartments. 
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 BMDC were permeablized and stained with antibodies to LAMP-1 (Green) and CPB1 (Red). 
Cells were fixed and imaged using confocal microscopy. Slides were imaged on an upright 
Olympus Fluoview 1000 at 60X. Data are representative of 2 independent experiments.  
 
 
 
 111 
APPENDIX B 
EFFECTS OF TOLERIZED DC ON THE EARLY CD4+ T CELL RESPONSE TO MUC1 
Previous work has shown that MUC1.Tg mice are hyporesponsive to immunization with MUC1p 
as determined by a number of correlates (i.e. cognate CD4+ T cell proliferation, MUC1p-specific 
IgG, IFNγ production, and specific lysis of MUC1+ tumor cells) (4, 5, 175). As these readouts 
are all part of the adaptive response, they were necessarily quantified between 5d-14d after 
immunization of WT and MUC1.Tg mice. Because tolerized DC produce less of the CD4-
chemotactic chemokines (i.e. MIP-1b, RANTES, and IL-16) 24h after vaccination (6), we 
hypothesized that there might exist a defect in the recruitment or retention of cognate CD4+ T 
cells in the spleen. Similarly, the interactions between DC that have low costimulatory molecule 
expression, are less inflammatory, and preferentially prime Foxp3+ Treg versus IFNγ+ effector T 
cells ex vivo would likely prime naïve, MUC1p-specific T cells differently in vivo than the more 
immunogenic DC from immunized WT mice. To determine the early effects of a tolerized 
splenic DC compartment on nascent T cell responses we transferred (i.v.) 5*106 CFSE-labeled, 
MUC1p-specific CD4+ T cells (VFT) into WT and MUC1.Tg recipients. After 24h, mice were 
immunized with DC:MUC1p and 24h later spleens harvested for FACS. The absolute number of 
VFT T cells that homed to, and were retained in, the spleens of WT and MUC1.Tg mice was 
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equivalent as was the number of total CD4+ T cells (Fig. 31). There were slightly more VFT cells 
that were CD25hi suggesting that the DC from immunized MUC1.Tg mice were beginning to 
prime a regulatory response. Ex vivo data previously demonstrated that these DC prime naïve T 
cells into Foxp3+ Treg in an antigen-specific manner after 7d in culture (6) so it is likely that 
after 1d of interaction between MUC1p-loaded DC and VFT T cells the beginning of a Treg 
response is being primed. As might be predicted, there was a higher frequency of CD69+ VFT T 
cells in the spleens of immunized WT mice (Fig. 31). Because human MUC1p represents a 
foreign Ag in WT mice, VFT T cells proliferate more compared to MUC1.Tg (4). This is 
reflected early on, within 24h of DC:T cell interactions and is likely mediated by splenic DC that 
are more immunogenic relative to MUC1.Tg.  
While there were no numerical differences in the pool of VFT T cells available to interact 
with tolerogenic or immunogenic DC, these data show that as early as 24h post-vaccination, the 
MUC1-specific CD4+ T cell response begins to diverge in WT and MUC1.Tg mice. This is 
supported by recent observations illustrating the maintenance of a higher frequency of Foxp3+ 
VFT T cells in MUC1.Tg mice compared to WT even after several weeks post-immunization 
(271).  
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Figure 31 DC from immunized MUC1.Tg mice do not activate MUC1p-specific CD4+ T cells as effectively as 
those from WT. 
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 5*106 CFSE-labeled, MUC1p-specific CD4+ T cells (VFT) were transferred (i.v.) into WT and 
MUC1.Tg recipients. 24h later, mice were immunized with DC:MUC1p and after an additional 
24h, spleens were harvested for FACS.  (A) Total number of MUC1p-specific CD4+ T cells 
(VFT). (B) Total number of all CD4+ T cells. (C) Percentage and (D) number of CD25hi VFT 
cells. (E) Percentage and number (F) of CD69+ VFT T cells. Bars represent Mean ± SEM, data 
representative of 2 independent experiments.  
B.1 DECREASED NUMBER OF SPLENIC DC IN IMMUNIZED MUC1.TG MICE 
CORRESPONDS TO A CONCURRENT INCREASE IN THE NUMBER OF NK CELLS. 
After immunization of MUC1.Tg mice there is a decrease both in the absolute number of 
CD11c+ splenic DC, as well as the DC used for immunization, compared to immunized WT. Part 
of this decrease is likely due to a defect in recruitment of CCR2+ DC to the spleen due to 
decreased DC-produced CCL2 compared to WT (Fig. 14). However, the decreased number of 
splenic DC could also be explained by cell death, either by apoptosis or direct killing. 
Specifically, CD8+ T cells and NK cells have been shown to kill iDC both in vitro and in vivo 
(272, 273). To examine the possibility that DC were being killed we examined concurrent 
changes in the number and phenotype of CD8+ T cells and NK cells. While there was no 
difference in the CD8+ population in the spleen 24h post-immunization, we observed a small but 
consistent increase in the frequency of NK1.1+ NK cells, and a significant increase in their 
absolute number in immunized MUC1.Tg mice relative to WT (Figs. 32A and 32C).  
 115 
 
Figure 32 Decrease in DC number after immunization of MUC1.Tg mice corresponds with a concurrent 
increase in the number of NK cells. 
WT and MUC1.Tg mice (n=3) were immunized with MUC1p. 24h later, spleens were harvested 
for FACS analysis. (A) Number of DC in spleens of immunized mice.  (B) Representative dot 
plot showing small increase in the frequency of NK1.1+ cells after immunization. (C) Number of 
NK cells in spleens of immunized mice. (A+C) Each point represents an individual mouse. Bars 
represent mean ± SEM. Data are pooled from 3-5 independent experiments.   
 
The integration of activating and inhibitory signals delivered to NK cells via their 
receptors determines whether the NK cell will lyse a target cell or not (274). Two of the best 
characterized interactions between NK cells and their targets are the ligation of the NK activating 
receptor NKG2D with its ligand Rae-1 (MICA/B in humans), and the killing of target cells with 
low MHC I expression, (275-277). Activated NK cells can be identified by expression of the 
early T/NK cell maker CD69 (278). Accordingly, we wanted to determine if the increased 
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number of NK cells was responsible for direct killing of DC in immunized MUC1.Tg mice. DC 
from MUC1.Tg mice did not differ in expression of Rae-1 or MHC 1 (data not shown). 
Phenotypic analysis of the NK compartment revealed a small, but statistically insignificant 
increase in the number of NK cells that were NKG2D+CD69+ in the spleens of immunized 
MUC1.Tg mice (Fig. 33A). This data suggested that there were no major differences in at least 
two canonical markers of NK activation between the two mice strains. To determine if there 
existed functional differences in the ability of NK cells to kill splenic DC we co-cultured DC 
from immunized WT and MUC1.Tg mice with NK cells isolated from a naïve animal overnight, 
followed by FACS staining for CD107a (LAMP-1), a marker of T/NK degranulation (279). 
There were no significant differences in degranulation of NK cells induced by DC from either 
strain (Fig. 33B). Finally, to determine if there was NK killing of DC through NKG2D-
independent pathways, we cultured DC recovered from immunized mice with naïve NK cells and 
used time lapse microscopy to visualize differences in DC:NK interactions and potential killing. 
As shown in Figs. 33C and 33D, there was no difference in cytolytic activity between groups, 
though there was a general trend towards increased duration of DC:NK contact when the DC 
were from immunized MUC1.Tg mice.  
These results suggest that the increased number of NK cells in immunized MUC1.Tg 
spleens are not killing DC but perhaps act as a compensatory source of IFNγ or play a regulatory 
role. Another possibility is that the NK are cytolytic but require an activation signal that is 
missing in ex vivo cultures, for example IL-2 and/or IL-15 (280). Similarly, the use of “naïve” 
NK cells in the assays above may preclude their effector functions, and different results would be 
obtained if NK cells from immunized mice were co-cultured with DC from the same animal.  
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Figure 33 Decrease in splenic DC after immunization of MUC1.Tg mice is not due to enhanced NK killing. 
(A) WT and MUC1.Tg (n=2) mice were immunized with soluble MUC1p admixed with 
Poly:ICLC. 24h later, spleens were harvested and stained for NK1.1, NKG2D and CD69. (B) DC 
isolated from immunized WT and MUC1.Tg mice were cultured together overnight at a 1:1 ratio 
with NK cells from a naïve mouse (5*104 cells/well), 1000U/mL of IL-2, and an anti-CD107a 
antibody. NK degranulation was quantified with flow cytometry staining for CD107a. (C+D) 
WT and MUC1.Tg mice were immunized with soluble MUC1p admixed with Poly:ICLC. 24h 
later DC were isolated and co-cultured overnight with naïve NK cells. Arrows show DC:NK 
interactions Timelapse DIC images were acquired at 1min intervals at a magnification of 20X. 
Bars represent mean ± SEM and data are representative of 2 (A), 1 (B), and 1 (C and D) 
experiments.  
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B.2 SPLENIC TREG IN IMMUNIZED WT AND MUC1.TG MICE 
Treg actively suppress DC expression of trypsin, CPB1, and elastase and by extension, inhibit 
DC immunogenicity. In vivo these effects are realized as early as 24h post-immunization and are 
therefore mediated by natural, or pre-existing, thymically-derived Treg. We were interested in 
any changes in the splenic Treg compartment after immunization, as an influx of MUC1p-
specific Treg in immunized MUC1.Tg mice might be efficient at rapidly suppressing protease 
expression by DC presenting MUC1p. To examine this, we immunized WT and MUC1.Tg mice 
and examined the frequency and phenotype of Treg at 24h. Figure 34 shows that immunization 
and mouse strain have no effect on the frequency or number of Treg at 24h. There were also no 
differences in the expression of IL-10, IL-2, and CTLA-4 (data not shown).  
Though there were no changes in Treg phenotype or frequency, the increased number of 
MUC1p-specific thymic Treg in MUCl.Tg mice likely accounts for the recognition of antigen-
bearing DC and suppresses enzyme expression in an antigen-specific manner. 
 
Figure 34 No difference in the frequency of splenic Treg post-immunization of WT and MUC1.Tg mice. 
WT and MUC1.Tg mice (n=3) were immunized with MUC1p. 24h later, spleens were harvested 
for FACS analysis. Dot plots are representative of data from 2 independent experiments.   
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APPENDIX C 
C.1 TRAFFICKING OF DC USED FOR VACCINATION 
Given the importance of MUC1-bearing DC in initiating ensuing tolerance or immunity in the 
spleen, we were interested in determining which tissues they localized to 24h after i.v. 
immunization. The majority of DC were located in the spleen, as expected, while a small number 
were found in lung. Almost none of the transferred DC were detected in a non-draining LN (Fig. 
35). 
 
Figure 35 DC predominantly localize to the spleen 24h after intravenous transfer. 
1*106 CFSE-labeled CD45.1 congenic BMDC were injected i.v. into MUC1.Tg (n=3) recipients. 
After 24h spleen, lung and non-draining (inguinal) LN were harvested and the percentage of DC 
determined by flow cytometry. Data are representative of 2 independent experiments. 
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C.2 MECHANISMS UNDERLYING GLOBAL CHANGES IN SPLENIC DC 
PHENOTYPE POST-IMMUNIZATION 
As discussed above (Section 5.2) a small number of the DC used for vaccination induce 
global, phenotypic changes within the majority of the endogenous DC compartment. Our data 
suggests that a hallmark of this phenotypic shift is the suppression of trypsin and CPB1 
expression in DC that is mediated by Treg, and likely MUC1p-specific Treg. The spleen of a 
typical 8-10 week old WT or MUC1.Tg mouse yields approximately 1.5-2*106 CD11c+ cells 
after positive selection via MACS (data not shown). Based on Fig. 35, an immunization 
consisting of 1*106 unloaded DC results in the detection of just 1.2*104 DC by flow cytometry in 
the spleen 24h later. Therefore, vaccine DC bearing MUC1p constitute approximately .6% of the 
total DC compartment in immunized animals. There are several mechanisms by which this 
paucity of cells might be able to induce changes in the entire endogenous DC compartment.  As 
referenced above, the vaccine DC might be taken up by resident APC resulting in the re-
presentation of MUC1p directly to cognate effector and regulatory T cells (263). While this 
mechanism would represent a partial amplification step as far as increasing the number of DC 
that are presenting MUC1p, it is unlikely that the phagocytosis/endocytosis of 1.2*104 vaccine 
DC would result in all endogenous APC presenting MUC1p, and thus being tolerized by MUC1-
specific Treg. To influence most resident cells, MUC1p must be presented by all splenic DC 
such that every DC interacts with a cognate Treg. Alternatively, relatively few DC:Treg 
interactions could occur with the resulting intracellular signals in DC being transmitted to the 
entire population. The widespread distribution of peptide antigen could occur via physical, 
tubular connections between DC, or by the shedding of MUC1-containing exosomes and their 
subsequent uptake, reprocessing, and presentation by recipient DC. Tunneling nanotubules 
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(TNT) are heterogeneous structures that allow transfer of both second messenger signaling 
molecules (i.e. Ca2+) as well as small molecular weight compounds (i.e. Lucifer yellow) from an 
individual DC to others that are distal by as much as several hundred microns (204). Therefore, 
TNT are candidate structures for disseminating MUC1 peptides as well as intracellular signaling 
molecules Alternatively, the ability of pMHC-containing exosomes to transfer antigen to distal 
DC has also been demonstrated (281).  
To begin to elucidate the mechanisms underlying global changes in DC phenotype we 
used multiphoton microscopy to examine the localization and interactions between the DC used 
for vaccination and endogenous CD11c+ cells in live splenic explants. Figure 36 shows the 
endogenous DC from a CD11c-YFP mouse just beneath the splenic capsule at a depth of 
approximately 50 microns. The vaccine-derived DC are predominantly located just underneath 
the (more medullary) endogenous population at a depth of 70-80 microns. 
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Figure 36 Localization of endogenous and vaccine-derived DC in a live splenic explant. 
24h after injection (i.v.) of a CD11c-YFP (n=1) mouse with 2*`106 DC:MUC1p labeled with 
Cy3 , the spleen was explanted and incubated in 37° RPMI and perfused with 95% O2  Images 
were collected using a Nikon A1R multiphoton system and a 25X, water immersion objective. 
(A) Image depth approximately 50 microns.  (B) Image depth approximately 70 microns. Data 
are from 1 experiment. 
 
While many injected DC home to a discrete location just beneath the layer of subcapsular 
resident DC, there are also areas shared by the two populations. Here, there are clear indications 
that endogenous DC have internalized some, but not all vaccine DC (Fig. 38) supporting the 
notion that the cells used to immunize are not exclusively the cells that ultimately present antigen 
to T cells. The morphology of the injected DC is small and rounded in contrast to the larger and 
more spread shape of resident cells. This may be due to enhanced apoptosis in vaccine DC 
and/or cells that are in the process of recovery after transfer. It is important to note that 
immunization of CD11c-YFP mice with MUC1p constitutes vaccination with a foreign antigen 
rather than a self-antigen. However, the mechanisms by which the endogenous DC network 
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interact with vaccine DC is likely to be similar regardless of the nature of the antigen introduced. 
Downstream, however, the types of T cell that DC presenting antigen interact with, the resultant 
T cell response, and the phenotype of the DC induced by cognate T cells are all intimately linked 
to the nature of the immunizing antigen.  
 
 
 
Figure 37 Vaccine-derived DC are internalized by endogenous DC. 
24h after injection (i.v.) of a CD11c-YFP mouse (n=1) with 2*106 DC:MUC1p labeled with Cy3 
, the spleen was explanted and incubated in 37° RPMI and perfused with 95% O2. The yellow 
arrow indicates an endogenous DC that has internalized a Cy3-labeled DC used for i.v. 
immunization. The white arrow indicates a Cy3-labeled DC that has not been internalized.  
Images were collected using a Nikon A1R multiphoton system and a 25X water immersion 
objective. Data are from 1 experiment. 
 
While many injected DC home to a discrete location just beneath the layer of subcapsular 
resident DC, there are also areas shared by the two populations. Here, there are clear indications 
that endogenous DC have internalized some, but not all vaccine DC (Fig. 37) supporting the 
notion that the cells used to immunize are not exclusively the cells that ultimately present antigen 
to T cells. The morphology of the injected DC is small and rounded in contrast to the larger and 
more spread shape of resident cells. This may be due to enhanced apoptosis in vaccine DC 
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and/or cells that are in the process of recovery after transfer. It is important to note that 
immunization of CD11c-YFP mice with MUC1p constitutes vaccination with a foreign antigen 
rather than a self-antigen. However, the mechanisms by which the endogenous DC network 
interact with vaccine DC is likely to be similar regardless of the nature of the antigen introduced. 
Downstream, however, the types of T cell that DC presenting antigen interact with, the resultant 
T cell response, and the phenotype of the DC induced by cognate T cells are all intimately linked 
to the nature of the immunizing antigen.  
Further experiments are required to determine if MUC1 is physically transported from 
either population to distal cells via tubules or exosomes, or if the endogenous DC network 
broadcasts signaling molecules from a relatively few number of DC to the population as a whole. 
These questions are well suited to a microscopy approach, however their technical execution is 
not trivial. Multiphoton imaging has the advantage of being able to penetrate deeper into living 
tissue without the heat damage and photobleaching associated with confocal lasers. However, 
structural resolution and magnification are limited using the multiphoton objective so a 
combination of both techniques in living animals, explanted tissue, and fixed tissue sections will 
be required.  
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